



PUBLICATIONS

1. Hans-S Jans, Daria Stypinski, Piyush Kumar , John R Mercer, Stephen A McQuarrie, Alexander J B McEwan, Leonard I Wiebe, Radiation Dosimetry of Theragnostic Pairs for Isotopes of Iodine in IAZA, *Pharmaceutics*, 2022 Aug 9;14(8):1655. doi: 10.3390/pharmaceutics14081655.
2. Terence A Riauka , Vickie E Baracos , Rebecca Reif , Freimut D Juengling , Don M Robinson , Marguerite Wieler, Alexander J B McEwan, Rapid Standardized CT-Based Method to Determine Lean Body Mass SUV for PET-A Significant Improvement Over Prediction Equations, *Front Oncol.* 2022 Jul 7;12:812777, doi: 10.3389/fonc.2022.812777
3. Virgolini I, Bahri S, Kjaer A, Grønbaek H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey- Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. *J Nucl Med.* 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936.
4. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. Miller CG, Grønbaek H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. *EJNMMI Res.* 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1.
5. A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. Miller CG, Grønbaek H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. *EJNMMI Res.* 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1.
6. Saravana-Bawan B, Bajwa A, Paterson J, McEwan AJB, McMullen TPW, Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta- analysis. *Clin Nucl Med.* 2019 Sep;44(9):719-727. doi: 10.1097/0000000000002646.
7. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasiaka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. *JAMA Oncol.* 2018 Nov 1;4(11):1597-1604. doi: 10.1001/jamaoncol.2018.2428.
8. Chu KP, Baker S, Zenke J, Morad A, Ghosh S, Morrish DW, McEwan AJBS, Williams DC, Severin D, McMullen TPW. Low-Activity Radioactive Iodine Therapy for Thyroid Carcinomas Exhibiting Nodal Metastases and Extrathyroidal Extension May Lead to Early Disease Recurrence. *Thyroid.* 2018 Jul;28(7):902-912. doi: 10.1089/thy.2017.0136.
9. Stypinski D, McQuarrie SA, McEwan AJB, Wiebe LI. Pharmacokinetics and Scintigraphic Imaging of the Hypoxia-Imaging Agent [123I]IAZA in Healthy Adults Following Exercise-Based Cardiac Stress. *Pharmaceutics.* 2018 Feb 22;10(1):25. doi: 10.3390/pharmaceutics10010025
10. Cai XY, Vijayaratnam N, McEwan AJB, Reif R, Morrish DW. Comparison of 30 mCi and 50 mCi I-131 doses for ablation of thyroid remnant in papillary thyroid cancer patients. *Endocr Res.* 2018 Feb;43(1):11-14. doi: 10.1080/07435800.2017.1346662. Epub 2017 Jul 25.
11. McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D, A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours., Citation: *CAN J SURG.* Apr 2017;60 (3):7616.



PUBLICATIONS - CONTINUED

14. Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJ, Castellani R, Lynch T, Shulkin B, Drobnic M, Staudenherz A, Ladenstein R, 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEX semi-quantitative reporting method by an international panel., Citation: EUR J NUCL MED MOL I. Feb 2017;44 (2):234-241. Prediction of hip fracture in elderly women. Miller CG, Porter RW. British Medical Journal 1991; 302:50 (letter to the editor).
15. Andersson JD, Wilson JS, Romaniuk JA, McEwan AJ, Abrams DN, McQuarrie SA, Gagnon K, Separation of [(99m) Tc] pertechnetate and molybdate using polyethylene glycol coated C18 and C30 resins. Appl. Radiat. Isot. 2016; 110:193-9. DOI:10.1016/j.apradiso.2016.01.016
16. Makis W1, Robinson D, McEwan AJ, Riauka TA., Chest X-ray Artifact Caused by Bilateral 99mTc-Antimony Trisulfite Injection for Sentinel Node Imaging in a Patient With Breast Cancer. CLIN NUCL MED. Apr 2016; (41):319-320
17. Makis W, McCann K, McEwan AJ, Sawyer MB., Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation., Clin Nucl Med. 2016 Mar;41(3):204-6. doi: 10.1097/RLU.0000000000000973.
18. Makis W, McCann K, McEwan AJ, Sawyer MB., Palliation of Extensive Metastatic Bone Disease With 223Ra-Dichloride α -Particle Therapy in a Patient With Malignant Hereditary Paraganglioma-Pheochromocytoma Syndrome With SDHB Mutation., Clin Nucl Med. 2016 Feb;41(2):144-7. doi: 10.1097/RLU.0000000000000964.
19. Makis W, McCann K, Riauka TA, McEwan AJ., Ectopic Corticotropin-Producing Neuroendocrine Tumor of the Pancreas Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy., Clin Nucl Med. 2016 Jan;41(1):50-2. doi: 10.1097/RLU.0000000000000971.
20. Makis W, McCann K, McEwan AJ., Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy: A Suggested Protocol., Clin Nucl Med. 2016 Jan;41(1):53-4. doi:10.1097/RLU.0000000000001023.
21. Makis W, McCann K, McEwan AJ. Metastatic Insulinoma Pancreatic Neuroendocrine Tumor Treated With 177Lu-DOTATATE Induction and Maintenance. Peptide Receptor Radionuclide Therapy: A Suggested Protocol. Clin Nucl Med. Jan 2016; 41 (1):53-4. PubMed PMID: 26562579
22. Makis W, McCann K, McEwan AJ, Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies. Clin Nucl Med. 2016 Feb;41(2):137-41.; PubMed PMID: 26447382
23. Makis W, McCann K, McEwan AJ, Sawyer MB, Combined Treatment with 131I-MIBG and Sunitinib Induces Remission in a Patient with Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome from an SDHB Mutation. Clin Nucl Med. 2016 Mar;41(3):204-6.; PubMed PMID: 26359568
24. Makis W, McCann K, Bryanton M, McEwan AJ, Cardiac Metastases of Neuroendocrine Tumors Treated With 177Lu DOTATATE Peptide Receptor Radionuclide Therapy or 131I-MIBG Therapy. Clin Nucl Med. Sept 2015, 40(12):962-964, PubMed PMID: 26359563
25. Makis W, Robinson D, McEwan AJ, Riauka TA. Chest X-ray Artifact Caused by Bilateral 99mTc-Antimony Trisulfite Injection for Sentinel Node Imaging in a Patient with Breast Cancer. Clin Nucl Med. Sept 2015, 41(4):319-20;. PubMed PMID: 26359561



PUBLICATIONS - CONTINUED

28. Makis W., McCann K., Raiuka T., McEwan A.J.B., Glucagonoma Pancreatic Neuroendocrinet Tumor Treated with 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy., *Clin Nucl Med.* 2015 Nov; 40(11):877-9.
29. Niedermoser S, Chin J, Wangler C, Kostikov A, Bernard-Gauthier V, Vogler N, Soucy JP, McEwan AJ, Schirmmacher R, Wangler B., In Vivo Evaluation of 18F-AiFalin-Modified TATE: A Potential Challenge for 68Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET., *J Nucl Med.* 2015 Jul;56(7):1100-5.
30. O. Boychak, L.J. Vos, W. Makis, F.-A. Buteau, N. Pervez, M. Parliament, A.J.B. McEwan, N. Usmani, Role for 11-C-Choline PET in Active Surveillance of Prostate Cancer., *Can. Urol. Assoc. J.*, 2015 Mar. 9(3-4): e98-103.
31. Makis W, McCann K, McEwan AJ, Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT., *Clin Nucl Med.* 2015 May;40(5)e278-81.
32. Siu-Chu Q, Sangha R, Spratlin J, Vos L., Mackey J, McEwan A.J.B, Venner P, Michelakis E, A Phase I Open-Labeled, Single-Arm, Dose-Escalation, Study of Dichloroacetate (DCA) in Patients with Advanced Solid Tumors. *Invest New Drugs.*, 2015 Jun;33(3):603-10., DOI: 10.1007/s10637-015-0221-y.
33. Makis W, McCann K, McEwan A.J.B, Incidental Acini Cell Carcinoma of the Parotid Gland Dicordant on 123I-MIBG, 111In-Octreotide, and 18F-FDG PET/CT in a Patient with Neuroendocrine Tumor of the Cecum., *Clin Nucl Med.* 2015 Aug;40(8):676-8.
34. Makis W, McCann K, McEwan A.J.B, Medullary Thyroid Carcinoma (MTC) treated with 177Lu-DOTATATE PRRT:a report of two cases., *Clin Nucl Med.* 2015 May; 40(5):408-12.
35. Makis W, McCann K, McEwan A.J.B, Esthesioneuroblastoma (olfactory neuroblastoma) treated with 111In-Octreotide and 177Lu-DOTATATE PRRT., *Clin Nucl Med.* 2015 Apr 40(4):317-21.
36. Bouvet V, Jans HS, Wuest M, Soueidan OM, Grant T, Mercer J, McEwan AJ, West FG, Cheeseman CI, Wuest F, Erratum: Automated synthesis and dosimetry of 6-deoxy-6-[18F]fluoro-D-fructose (6-[18F]FDF): a radiotracer for imaging of GLUT5 in breast cancer., *AM J Nucl Med Mol Imaging.* 2014 Dec 15;5(1):95.
37. Makis W, McCann K, McEwan A.J.B, Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT., *Clin Nucl Med.* 2015 Mar;40(3):237-40.
38. Makis W, McCann K, McEwan A.J.B, Extraventricular neurocytoma treated with 177Lu DOTATATE PRRT induction and maintenance therapies., *Clin Nucl Med.* 2015 Mar 40(3):234-6.
39. Makis W., McCann K., Buteau FA, McEwan A.J.B, Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy., *Clin Nucl Med.* 2015 Aug;40(8)663-6.
40. Makis W., McCann K., Buteau FA, McEwan A.J.B, Resolution of Malignant Ascites and Stabilization of Metastases in a Patient With Small Bowel Neuroendocrine Tumor With 177Lu-DOTATATE Following Progression After 17 131I-MIBG Treatments and Chemotherapy., *Clin Nucl Med.* 2015 Jul; 40(7):564-6.
41. Makis W, McCann K, Buteau FA, McEwan A.J.B, Liver and Bone Metastases from Small Bowel Neuroendocrine Tumor Respond to 177Lu-Dotatate induction and maintenance therapies. *Clin. Nucl. Med.*, 2015 Feb; 40(2):162-5.
DOI: 10.1007/s10637-015-0221-y



PUBLICATIONS - CONTINUED

44. McEwan AJB. The Leading Edge of Nuclear Medicine. *International Innovation*. 2013; 30-33.
45. Amanie J, Jans HS, Wuest M, Pervez N, Murtha A, Usmani N, Yee D, Pearcey R, Danielson B, Patel S, Macewan R, Field C, Robinson D, Wilson J, Lewis D, Parliament M, McEwan AJ., Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy., *Curr Oncol*; 2013;20(2): (104-10).
46. Mercer JR, McEwan AJ, Wiebe LI., [131I]IAZA as a molecular radiotherapeutic (MRT) drug: wash-out with cold IAZA accelerates clearance in a murine tumor model., *Curr Radiopharm.*, 2013: 6(2): (87-91).
47. Roa WH, Yaremko B, McEwan A, Amanie J, Yee D, Cho J, McQuarrie S, Riauka T, Sloboda R, Wiebe L, Loebenberg R, Janicki C. Dosimetry Study of [I-131] and [I-125]- Meta-Iodobenzyl Guanidine in a Simulating Model for Neuroblastoma Metastasis. *Technol Cancer Res Treat*. 2013;12(1):79-90
48. Vickers MM, Pasioka J, Dixon E, McEwan S, McKay A, Renouf D, Schellenberg D, Ruether D. Report from the 13th Annual Western Canadian Gastrointestinal Cancer Consensus Conference: Calgary, Alberta Sept 8 - 10, 2011. *Curr. Oncol*. 2012;19(6)e-468-477
49. Gagnon K, Wilson JS, Holt CM, Abrams DN, McEwan AJ, Mitlin D, McQuarrie SA. Cyclotron Production of 99mTc: recycling of enriched 100Mo Metal Targets. *Applide Radiat. Isot*. 2012;84(2):437-42
50. Jha N, Harris J, Seikaly H, Jacobs JR, McEwan AJ, Robbins KT, Grecula J, Sharma AK, Ang KK. A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244). *Int J Radiat Oncol Biol Phys*. 2012;84(2):(437-42)
51. AA El-Mabhouh, PN Nation, JT Abele, T Riauka, E. Postema, McEwan AJB, JR Mercer. A Conjugate of Gemcitabine with Bisphosphonate (Gem/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases. *Onc. Res.*, 2011; Vol 9:1-100.
52. Wuest M, Trayner BJ, Grant TN, Jans HS, Mercer JR, Murray D, West FG, McEwan AJB, Wuest F, Cheeseman CI. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. *Nucl Med Biol*. May 2011;38(4):(461-75).
53. Gagnon K, McQuarrie S, Abrams D, McEwan AJB, Wuest F. Radiotracers Based on Technetium-94m Current Radiopharmaceuticals. 2011;4:(90-101)
54. Kerhet A, Small C, Quon H, Riauka T, Schrader L, Greiner R, Yee D, McEwan A, Roa W. Application of Machine Learning Methodology for PET-Based Definition of Lung Cancer. *Current Oncology*, 2010, 17(1): 41-43.
55. Kumar P, Naimi E, McEwan AJ, Wiebe LI. Synthesis, Radiofluorination, and Hypoxia-selective Studies of FRAZ: A Configurational and Positional Analogue of the Clinical Hypoxia Marker [18F]-FAZA. *Bioorg Med Chem*, 2010; 18(6):2255-2264.
56. Paproski RJ, Wuest M, Jans HS, Graham K, Gati WP, McQuarrie S, McEwan A, Mercer J, Young JD, Cass CE. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. *J Nucl Med*, 2010; 51(9):1447-55.
57. Vickers MM and McEwan AJB. Therapeutic Radiopharmaceutical Development (in) with GNM and Molecular Imaging in the Clinical



PUBLICATIONS - CONTINUED

59. Suchak AA, Millo N, MacEwan R, McEwan AJB. Neuroendocrine Differentiated Breast Carcinoma with Pleural Metastases Using Indium-111 Octreotide. *Clin Nucl Med*, 2009; 34:74-75.
60. McEwan A, Graham MM, Conti PS. SNM Newsline: SNM Molecular Imaging Summit Introduces Clinical Trials Network. *J Nucl Med*, 2009; 50(4):18N.
61. Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial Results of Hypoxia Imaging Using 1- α -D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). *Eur J Nucl Med Mol Imaging*, 2009; 36: 1565-1573.
62. Postema EJ and McEwan AJB. Radioiodinated Metaiodobenzylguanidine Treatment of Neuroendocrine Tumors in Adults. *Cancer Biotherapy and Radiopharmaceuticals*, 2009; 24(5): 519-525.
63. Kumar P, Emami S, Kresolek Z, Yang J, McEwan AJ, Wiebe LI. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides. *Med Chem*, 2009; 5(2):118-129.
64. McEwan AJB, Graham MM, Conti PS. Site Qualification in Multicenter Clinical Trials. *J Nucl Med*, 2009; 50(8): 30N.
65. McEwan AJB. Continuing and Accumulating Successes. *J. Nucl Med* 2008; 49(2): 16N-18N.
66. Kumar P, Emami S, McEwan AJB, Wiebe LI. Stereospecific deuteration of β -furanosyl azomycin nucleosides; a model reaction for tritium radiolabeling. *Bioorganic & Medicinal Chemistry Letters*, 2008; 18(11):3256-3260.
67. McEwan AJB, Van Brocklin HF, Divgi C. Action Plan for Emerging Molecular Imaging Technologies. JNM White Paper. *J Nucl Med* 2008; 49(2):37N-41N.
68. Sangha GS, Severin D, Postema E, McEwan A, Stewart K. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography and EUS. *Gastrointest Endosc*, 2008; 67(3):402-409.
69. McEwan AJB. SNM Leadership Update: A Look Back at a Year of Extraordinary Success and Forward to a Rewarding Future. *J Nucl Med*, 2008; 49(6): 80N-81N.
70. Conti PS, McEwan AJB, Pomper MG. SNM Newsline: Molecular Imaging: The Future of Modern Medicine. *J Nucl Med*, 2008; 49(6):16N-20N.
71. Kong T, Zeng J, Wang X, Yang X, Yang J, McQuarrie S, McEwan A, Roa W, Chen J, Xing JZ. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. *Small*, 2008; 4(9):1537-1543.
72. Sharma SK, Zheng W, Joshua AV, Abrams DN, McEwan AJB. Synthesis and Evaluation of Novel 4-amino-4,6-androstadiene-3,17-dione: An Analog of Formestane. *Bioorganic & Medicinal Chemistry Letters*, 2008; 18(20): 5563-5566.
73. Murray D and McEwan AJ. Radiobiology of Systemic Radiation Therapy. *Cancer Biotherapy and Radiopharmaceuticals* 2007, 22(1):1-23.
74. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JA, Coldwell D. Recommendations for Radionembolization of Hepatic Malignancies Using Yttrium-90 (Y90) Microsphere Brachytherapy: A



PUBLICATIONS - CONTINUED

76. Joshua A, Sharma SK, Strelkov A, Scott JR, Martin-Iverson MT, Abrams DN, Silverstone PH, McEwan AJB. Synthesis and Biodistribution of 8-Iodo-11-(4-methylpiperazino)-5H-dibenzo[b,e][1,4]-diazepine: lozapine. *Bioorg Med Chem Lett* 2007; 17: 4066-4069.
77. Drever L, Roa W, McEwan A, Robinson D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. *J Appl Clin Med Phys* 2007; 8(2): 93-109.
78. Drever L, Roa W, McEwan A, Robinson D. Iterative threshold segmentation for PET target volume delineation. *Med Phys* 2007; 34(4): 1253-1265.
79. McEwan AJB. SNM Leadership Update: Molecular Imaging...Realistically...An Evolution in Nuclear Medicine Practice. *J Nucl Med*, 2007; 48(8): 31N, 38N.
80. McEwan AJB. How Do We Introduce the Next Generation of Radiotracers into Clinical Practice? SNM Leadership Update, *J Nucl Med*, 2007; 48(9): 28N, 30N.
81. Kumar P, Mercer, J, Doerksen C, Tonkin K, McEwan AJB. Clinical production, stability studies and PET imaging with 16- α -[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. *J Pharm Pharmaceut Sci*, 2007; 10(2); 256s-265s.
82. Emami S, Kumar P, Yang J, Kresolek Z, Paproski R, Cass C, McEwan AJB, Wiebe LI. Synthesis, transport and hypoxia-selective binding of 1- β -D-(5-deoxy-5-fluororibofuranosyl)-2-nitroimidazole (β -5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. *J Pharm Pharmaceut Sci*, 2007; 10(2): 237-245.
83. McEwan AJB. SNM Leadership Update: Funding Nuclear Medicine Research. *J Nucl Med*, 2007; 48(11); 23N.
84. McEwan AJB. Radiation Rules are Strict. Letter. *USA Today*, November 28, 2007.
85. McEwan AJB. SNM Leadership Update: Advocating for PET/CT. *J Nucl Med*, 2007; 48(12): 26N.
86. Drever L, Robinson DM, McEwan AJB, Roa W. A Local Contrast Based Approach to Threshold Segmentation for PET Target Volume Delineation. *Medical Physics* 2006; 33(6):1583-1594.
87. Gulenchyn KY, McEwan AJ, Freeman M, Kiess M, O'Neill BJ, Beanlands RS, CANM, CSS. Treating the right patient at the right time: access to cardiovascular nuclear imaging. *Can J Cardiol* 2006; 22(1):827-833.
88. Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J, Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. *Clin Invest Med* 2006; 29(5):301-311.
89. Sandler MP, McEwan AJ. Revolutionizing the Future. *RT Image* 2006; 19(45). (www.rt-image.com.)
90. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, Wester H-J, Beck R, McEwan AJB, Wiebe LI, Schwaiger M. Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside. *J Nucl Med* 2005; 46: 106-113.
91. Yaremko B, Riauka T, Robinson D, Murray B, McEwan A, Roa W. Threshold Modification for Tumour Imaging in Non-Small-Cell Lung Cancer Using Positron Emission Tomography. *Nuc Med Commun* 2005; 26(5): 433-440.

**PUBLICATIONS - CONTINUED**

94. Morin KW, Duan W, Knaus EE, McEwan AJB, Wiebe LI. A Human Osteosarcoma Cell Line Expressing Herpes Simplex Type-1 Thymidine Kinase: Studies with Radiolabeled (E)-5-(2-iodovinyl)-2'-fluoro-2'-deoxyuridine. *Nucl Med Biol* 2005; 32(5):459-464.
95. Naimi E, Kumar P, McEwan AJB, Wiebe LI. A one-pot synthesis of 1-alpha- and 1-beta-D-arabinofuranosyl-2-nitroimidazoles: Synthons to the Markers of Tumor Hypoxia. *Nucleosides Nucleotides Nucleic Acids* 2005; 24(3):173-178.
96. Yaremko B, Riauka T, Robinson D, Murray B, Alexander A, McEwan AJB, Roa W. Thresholding in PET images of static and moving targets. *Phys Med Biol* 2005; 50:1-14.
97. McEwan AJB. Does Health Technology Assessment Put Patient Care at Risk? (Comment) *J Nucl Med* 2005; 46(12): 1939.
98. Morin KW, Duan W, Xu L, Zhou A, Moharram S, Knaus EE, McEwan AJB, Wiebe LI. Cytotoxicity and Cellular Uptake of Pyrimidine Nucleosides for Imaging Herpes Simplex Type-1 Thymidine Kinase (HSV-1 TK) Expression in Mammalian Cells. *Nucl Med Biol*, 2004, 31(5):623-630.
99. Paty BW, Bonner-Weir S, Laughlin, MR. McEwan AJ, Shapiro AM. Toward Development of Imaging Modalities for Islets after Transplantation: Insights from the National Institutes of Health Workshop on Beta Cell Imaging. *Transplantation* 2004; 77(8):1133-1137.
100. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJB, Halperin R, Roa WH. Results of a Phase I Study to Dose Escalate Using Intensity Modulated Radiotherapy Guided by Combined PET/CT Imaging with Induction Chemotherapy for Patients with Non-Small Cell Lung Cancer. *Radiother Oncol* 2004; 73: 285-287.
101. Sywak MS, Pasiaka JL, McEwan AJB, Kline G, Rorstad O. 131I-Meta-iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors. *World J Surg* 2004; 28: 1157-1162.
102. El-Mabhouh A, Angelov C, McEwan A, Jia G, Mercer J. Preclinical Investigations of Drug and Radionuclide Conjugates of Bisphosphonates for the Treatment of Metastatic Bone Cancer. *Cancer Biotherapy & Radiopharmaceuticals* 2004; 19(5): 627-640.
103. Pasiaka JK, McEwan AJB, Rorstad O. The palliative role of 131I-MIBG and 111In-Octreotide Therapy in Patients with Metastatic Progressive Neuroendocrine Neoplasms. *Surgery*. 2004; 136(6):1218-1226.
104. Demeter S, Chmielowiec C, Logus W, Benkovska-Angelova P, Jacobs P, Hailey D, McEwan AJB. The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Multivariate Analysis of Survival to Two Years. *Can Resp J* 2003;10(8):435-441.
105. McEwan AJB. Radioisotope Therapy and Clinical Trial Design: The Need for Consensus and Innovation. Invited Commentary. *J Nucl Med* 2002; 43(1): 87-88.
106. Angelov CM, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 3-Methyl-1,2-butadienyl-1,1-diphosphonate(1-). *Acta Crystallographica* 2002; E58: o498-o500.
107. Angelov CM, Mazzuca DA, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 2-(3-Methyl-1,2-butadienyl)-2-oxo-1,3,2-oxazaphosphorinane. *Acta Crystallographica* 2002; E58: o399-o401.
108. Wiebe LI and McEwan AJB. Scintigraphic Imaging of Focal Hypoxic Tissue: Development and Clinical Applications of 123I-IAZA. *Brazilian Archives of Biology and Technology* 2002; 45 (Special n):69-81

**PUBLICATIONS - CONTINUED**

112. Morin KW, Duan W, Knaus EE, McEwan AJB, Wiebe LI. A Human Osteosarcoma Cell Line Expressing Herpes Simplex Type-1 Thymidine Kinase: Studies with Radiolabeled (E)-5-(2-iodovinyl)-2'-fluoro-2'-deoxyuridine. *Nucl Med Biol* 2005; 32(5):459-464.
113. Naimi E, Kumar P, McEwan AJB, Wiebe LI. A one-pot synthesis of 1-alpha- and 1-beta-D-arabinofuranosyl-2-nitroimidazoles: Synthons to the Markers of Tumor Hypoxia. *Nucleosides Nucleotides Nucleic Acids* 2005; 24(3):173-178.
114. Yaremko B, Riauka T, Robinson D, Murray B, Alexander A, McEwan AJB, Roa W. Thresholding in PET images of static and moving targets. *Phys Med Biol* 2005; 50:1-14.
115. McEwan AJB. Does Health Technology Assessment Put Patient Care at Risk? (Comment) *J Nucl Med* 2005; 46(12): 1939.
116. Morin KW, Duan W, Xu L, Zhou A, Moharram S, Knaus EE, McEwan AJB, Wiebe LI. Cytotoxicity and Cellular Uptake of Pyrimidine Nucleosides for Imaging Herpes Simplex Type-1 Thymidine Kinase (HSV-1 TK) Expression in Mammalian Cells. *Nucl Med Biol*, 2004, 31(5):623-630.
117. Paty BW, Bonner-Weir S, Laughlin, MR. McEwan AJ, Shapiro AM. Toward Development of Imaging Modalities for Islets after Transplantation: Insights from the National Institutes of Health Workshop on Beta Cell Imaging. *Transplantation* 2004; 77(8):1133-1137.
118. Holloway CL, Robinson D, Murray B, Amanie J, Butts C, Smylie M, Chu K, McEwan AJB, Halperin R, Roa WH. Results of a Phase I Study to Dose Escalate Using Intensity Modulated Radiotherapy Guided by Combined PET/CT Imaging with Induction Chemotherapy for Patients with Non-Small Cell Lung Cancer. *Radiother Oncol* 2004; 73: 285-287.
119. Sywak MS, Pasiaka JL, McEwan AJB, Kline G, Rorstad O. 131I-Meta-iodobenzylguanidine in the Management of Metastatic Midgut Carcinoid Tumors. *World J Surg* 2004; 28: 1157-1162.
120. El-Mabhough A, Angelov C, McEwan A, Jia G, Mercer J. Preclinical Investigations of Drug and Radionuclide Conjugates of Bisphosphonates for the Treatment of Metastatic Bone Cancer. *Cancer Biotherapy & Radiopharmaceuticals* 2004; 19(5): 627-640.
121. Pasiaka JK, McEwan AJB, Rorstad O. The palliative role of 131I-MIBG and 111In-Octreotide Therapy in Patients with Metastatic Progressive Neuroendocrine Neoplasms. *Surgery*. 2004; 136(6):1218-1226.
122. Demeter S, Chmielowiec C, Logus W, Benkovska-Angelova P, Jacobs P, Hailey D, McEwan AJB. The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Multivariate Analysis of Survival to Two Years. *Can Resp J* 2003;10(8):435-441.
123. McEwan AJB. Radioisotope Therapy and Clinical Trial Design: The Need for Consensus and Innovation. Invited Commentary. *J Nucl Med* 2002; 43(1): 87-88.
124. Angelov CM, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 3-Methyl-1,2-butadienyl-1,1-diphosphonate(1-). *Acta Crystallographica* 2002; E58: o498-o500.
125. Angelov CM, Mazzuca DA, van den Heever JP, McDonald R, McEwan AJB, Mercer JR. 2-(3-Methyl-1,2-butadienyl)-2-oxo-1,3,2-oxazaphosphorinane. *Acta Crystallographica* 2002; E58: o399-o401.
126. Wiebe LI and McEwan AJB. Scintigraphic Imaging of Focal Hypoxic Tissue: Development and Clinical Applications of 123I-IAZA. *Brazilian Archives of Biology and Technology* 2002; 45 (Special n):69-81

PUBLICATIONS - CONTINUED

130. Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, McEwan AJB. Radioiodinated N-[3-(4-Morpholino)Propyl]-N-Methyl-2-Hydroxy-5-Iodo-3-Methyl-benzylamine (ERC9): A New Potential Melanoma Imaging Agent. *Eur J Nucl Med* 2001; 28(4): 408-417.
131. Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJB. Pharmacokinetic Estimations for 123I-IAZA in Healthy Volunteers. *J Nucl Med* 2001; 42(9):1418-1423.
132. Lee HC, Kumar P, McEwan AJB, Wiebe LI, Mercer JR. Synthesis, Radiolabelling and Biodistribution of Putative Metabolites of Iodoazomycin Arabinoside (IAZA). *Nucl Med Biol* 2000; 27(1): 61-68.
133. Morin KW, Knaus EE, Wiebe LI, Xia H, McEwan AJB. Reporter Gene Imaging: Effects of Ganciclovir Treatment on Nucleoside Uptake, Hypoxia and Perfusion in a Murine Gene Therapy Tumour Model that Expresses Herpes Simplex Type-1 Thymidine Kinase. *Nucl Med Commun* 2000; 21: 129-137.
134. McEwan AJB. Use of Radionuclides for the Palliation of Bone Metastases. *Semin Radiat Oncol* 2000; 10(2): 103-114.
135. Kumar P, Stypinski D, Xia H, McEwan AJB, Machulla H-J, Wiebe LI. Fluoroazomycin Arabinoside (FAZA): Synthesis, 2H and 3H-labelling and Preliminary Biological Evaluation of a Novel 2-Nitroimidazole Marker of Tissue Hypoxia. *J Lab Comp Radiopharmaceuticals* 1999; 42:3-16.
136. Lythgoe MF, Williams SR, Busza AL, Wiebe L, McEwan AJB, Gadian DG, Gordon I. The Relationship Between Magnetic Resonance Diffusion Imaging and Autoradiographic Markers of Cerebral Blood Flow and Hypoxia in an Animal Stroke Model. *J Magnetic Resonance in Medicine* 1999; 41:706-714.
137. Stypinski D, Wiebe LI, McEwan AJB, Schmidt RP, Tam YK, Mercer JR. Clinical Pharmacokinetics of 123I-IAZA in Healthy Volunteers. *Nucl Med Commun* 1999; 20: 559-567.
138. Vinjamuri S, O'Driscoll K, Maltby P, McEwan AJB, Wiebe LI, Critchley M. Identification of Hypoxic Regions in Traumatic Brain Injury. *Clin Nucl Med* 1999; 24(11): 891-892.
139. Roa WHY, Miller GG, McEwan AJB, McQuarrie SA, Tse JC, Wu J, Wiebe LI. Targetted Radiotherapy of Multicell Neuroblastoma Spheroids with High Specific Activity [¹²³I]meta-iodobenzylguanidine. *Int J Radiat Oncol Biol Phys* 1998; 41(2): 425-432.
140. McQuarrie SA, Riauka T, Baum RP, Sykes TR, Boniface G, MacLean GD, Noujaim AA, McEwan AJB. The Effects of Circulating Antigen on the Pharmacokinetics and Radioimmunosintigraphic Properties of ^{99m}Tc Labelled Monoclonal Antibodies in Cancer Patients. *J Pharm and Pharmaceutical Sciences* 1998; 1(3): 115-125.
141. McEwan AJB. Palliative Therapy with Bone Seeking Radiopharmaceuticals. *Cancer Biotherapy & Radiopharmaceuticals* 1998; 13(6): 413-426.
142. Johnson MA, Davis P, McEwan AJB, Jhangri GS, Warshawski R, Gargum Ali, Ethier J, Anderson WW. Preliminary Findings from a Teleultrasound Study in Alberta. *Telemedicine Journal* 1998; 4(3): 267-276.
143. Lythgoe MF, Williams SR, Wiebe LI, McEwan AJB, Gordon I. Autoradiographic Imaging of Cerebral Ischaemia Using a Combination of Blood Flow and Hypoxic Markers in an Animal Model. *Eur J Nucl Med* 1997; 24(1): 16-20.
144. Tibbo P, Silverstone PH, McEwan AJB, Scott J, Joshua A, Golberg K. A Single Photon Emission Computed Tomography Scan Study of Striatal Dopamine D2 Receptor Binding with 123I-Epidopride in Schizophrenic Patients and Controls. *J Psychiatry and Neurosci* 1997; 22(1):39-45.

**PUBLICATIONS - CONTINUED**

148. McQuarrie SA, Baum RP, Niesen A, Madiyalakan R, Korz W, Sykes TR, Sykes CJ, Hör G, McEwan AJB, Noujaim AA. Pharmacokinetics and Radiation Dosimetry of 99Tcm-labelled Monoclonal Antibody B43.13 in Ovarian Cancer Patients. *Nucl Med Commun*, 1997; 18: 878-886.
149. Dessureault S, Koven R, Reilly RM, Couture J, Schmocker B, Damani M, Kirsh J, Ichise M, Sidlofsky S, McEwan AJB, Boniface G, Stern H, Gallinger S. Pre-operative Assessment of Axillary Lymph Node Status in Patients with Breast Adenocarcinoma Using Intravenous 99mTechnetium mAb-170H.82 (Tru-Scint@AD™). *Breast Cancer Research and Treatment* 1997; 45: 29-37.
150. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C, Chapman JD. Measurement of Hypoxia in Human Tumors by Non-Invasive SPECT Imaging of Iodoazomycin Arabinoside. *Br J Cancer*, 1996; 74 (Suppl. 27): S209-S212.
151. Carson BJW, McEwan AJB, Hoskinson ME, Maguire CG. Detection of an Abdominal Mycotic Aneurysm on Three-Phase Bone Scan: A Case Report. *Clin Nucl Med* 1995; 20(3): 267-269.
152. Martin WRW, Hoskinson M, Kremer B, Maguire C, McEwan AJB. Functional Caudate Imaging in Symptomatic Huntington's Disease: Positron Emission Tomography versus Single-Photon Emission Computed Tomography. *J Neuroimag* 1995; 5: 227-232.
153. Griffiths DJ, McCracken PN, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J. Cerebral aetiology of urinary urge incontinence in the elderly. *Age and Aging* 1994; 23: 236-250.
154. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron (Strontium-89 Chloride) in Patients with Prostate Cancer Metastatic to Bone. *Nuc Med Commun* 1994; 15: 499-504.
155. McQuarrie SA, Baum RP, Golberg L, Niesen A, Golberg K, Noujaim AA, McEwan AJB. A Pharmacokinetic Comparison of Murine and Chimeric Forms of the 99mTc Labelled 174H.64 Monoclonal Antibody. *J Nucl Biol Med* 1994; 38 (Suppl. 1 to No. 4): 140-144.
156. Al-Arafaj A, Ryan EA, Hutchison K, Mannan RH, Mercer J, Wiebe LI, McEwan AJB. An Evaluation of 123I-Iodoazomycin arabinoside ([123I]-IAZA) as a Marker of Localized Tissue Hypoxia in Patients with Diabetes Mellitus. *Eur J Nucl Med* 1994; 21: 1338-1342.
157. Dawson MRW, Dobbs A, Hooper HR, McEwan AJB, Triscott J, Cooney J. Artificial Neural Networks that Use Single-Photon Emission Tomography to Identify Patients with Probable Alzheimer's Disease. *Eur J Nucl Med* 1994; 21: 1303-1311.
158. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA, Porter AT. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron in Patients with Prostate Cancer Metastatic to Bone. *Eur Urol* 1994; 26 (Suppl 1): 26-31.
159. McEwan AJB. Pain palliation and nuclear medicine. (Editorial) *Eur J Nuc Med*, 1993; 20: 1-3.
160. Moore RB, Chapman JD, Mercer JR, Mannan RH, Wiebe LI, McEwan AJB, McPhee MS. Measurement of PDT-induced hypoxia in the Dunning prostate tumors by Iodine-123-iodoazomycin arabinoside. *J Nuc Med*, 1993; 34: 405-413.
161. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE, Crook J, Gulenchyn KY, Hong KE, Wesolowski C, Yardley J. Results of a randomized phase III trial to evaluate the efficacy of Strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiation Oncology Biol Phys*. 1993; 25: 905-913.

**PUBLICATIONS - CONTINUED**

165. Ignaszewski AP, McCormick LX, Heslip PG, McEwan AJB, Humen DP. Safety and Clinical Utility of Combined Intranavenous Dipyridamole/Symptom-Limited Exercise Stress Test with Thallium-201 Imaging in Patients with Known or Suspected Coronary Artery Disease. *J Nucl Med* 1993; 34: 2053-2061.
166. McEwan AJB, MacLean GD, Hooper HR, Sykes T, McQuarrie SA, Golberg L, Bodnar DM, Lloyd SL, Noujaim AA. MAb 170H.82: An Evaluation of a novel panadenocarcinoma monoclonal antibody labelled with Technetium-99m and with Indium-111. *Nuc Med Commun*, 1992; 13: 11-19.
167. Parliament MB, Chapman JD, Urtasun RC, McEwan AJB, Golberg L, Mercer JR, Mannan RH, Wiebe LI. Non-invasive assessment of human tumour hypoxia with 123I-Iodoazomycin Arabinoside: Preliminary report of a clinical study. *Br J Cancer*, 1992; 65: 90-95.
168. Jen H, Tracey K, Catz Z, McEwan AJB. Bone scan appearance of diastasis pubis in association with congenital extrophy of the bladder. *Clin Nuc Med*, 1992; 17:47.
169. Moore RB, Chapman JD, Mokrzanowski AD, Arnfield MR, McPhee MS, McEwan AJB. Non-invasive monitoring of photodynamic therapy with 99mTechnetium HMPAO. *Br J Cancer*, 1992; 65:491-497.
170. Champion PE, Groshar D, Hooper HR, Palmer M, Catz Z, Belch A, McEwan AJB. Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkin's lymphoma? *Nuc Med Commun*, 1992; 13:730-737.
171. McEwan AJB, Jackson FI, Catz Z, Schmidt RP, Hooper HR, Matthews JJD. Tc-99m hexamethylpropyleneamine oxime (HMPAO) to demonstrate diffuse cortical necrosis in-vivo. *Clin Nuc Med*, 1991; 16,3: 167-169.
172. MacLean GD, McEwan AJB, Noujaim AA, Hooper HR, Sykes TR, Bodnar DM, Lloyd S, Golberg LE, Longenecker BM. Two novel monoclonal antibodies have potential for gynecologic cancer imaging. *Antibody, Immunoconjugates & Radiopharmaceuticals*, 1991; 4,3: 297-308.
173. Lewington VJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA, McEwan AJB. A prospective, randomised double-blind crossover study to examine the efficacy of Strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer*, 1991; 27,8: 954-958.
174. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJB, Macleod PA, Zivanovic MA. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. *Br J Rad*, 1991; 64: 816-822.
175. Tracey KP, Jen H, Metcalfe JB, McEwan AJB. Case report: Autosomal recessive (infantile) polycystic kidney disease demonstrated by Tc-99m DMSA renal imaging. *Clin Nuc Med*, 1991; 16,11: 833-835.
176. Lewington VJ, Zivanovic MA, Tristram M, McEwan AJB, Ackery DM. Radiolabelled Metaiodobenzylguanidine Targeted Radiotherapy for Malignant Pheochromocytoma. *J Nucl Biol Med*, 1991; 35: 280-283.
177. McEwan AJB, Porter AT, Venner PM, Amyotte G. An evaluation of the safety and efficacy of Treatment with Strontium-89 in Patients who have previously received wide field radiotherapy. *Antibody, Immunoconjugates & Radiopharmaceuticals* 1990; 3,2: 91-98.
178. Hooper HR, McEwan AJB, Lentle BC, Kotchon TL, Hooper PM. Interactive three dimensional region of interest analysis of HMPAO SPECT brain studies. *J Nucl Med* 1990; 31,12: 2046-2051.

**PUBLICATIONS - CONTINUED**

182. Thompson JF, Clifford PC, McEwan AJB, Chant AD. Case Report: Pheochromocytoma and Abdominal Aneurysm: Confirmation of Diagnosis after Aortic Surgery using mIBG Imaging. *Eur J Vasc Surg* 1989; 3: 457-459.
183. McQuarrie SA, Ung Y, McEwan AJB. 99mTc hexamethyl propyleneamine oxime (HMPAO)--an animal model of tumor perfusion. *Proceedings of the International Association of Radiopharmacology* 1989: 96-103.
184. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJB, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. *J Nucl Med* 1988; 29: 549-557.
185. Jha N, McEwan AJB. Distinguishing metastatic prostate cancer and Paget's disease. *Diagnosis*, June, 1988: 135-139.
186. Blake GM, Zivanovic MA, McEwan AJB, Condon BR, Ackery DM. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma and neuroblastoma. *Br J Radiol* 1987; 60: 253-259.
187. Von Moll L, McEwan AJB, Shapiro B, Sisson JC, Gross MD, Lloyd R, Beals E, Beierwaltes WH, Thomson NW. Iodine-131 mIBG scintigraphy of neuroendocrine tumors other than pheochromocytoma and neuroblastoma. *J Nucl Med* 1987; 28: 979-988.
188. Blake GM, Zivanovic MA, McEwan AJB, Batty VB, Ackery DM. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. *Eur J Nucl Med* 1987; 13: 41-46.
189. Blake GM, Gray JM, Zivanovic MA, McEwan AJB, Fleming JS, Ackery DM. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. *Br J Radiol* 1987; 60: 685-692.
190. Tippett PA, West RS, McEwan AJB, Ackery DM. A comparison of dopamine and homovanillic acid excretion, as prognostic indicators in malignant pheochromocytoma. *Clin Chem Acta* 1987; 166: 123-133.
191. McEwan AJB, Davis CL, Ackery DM. Bladder pheochromocytoma diagnosed by radioiodinated meta iodobenzylguanidine imaging. *Br J Urol* 1987; 30: 594-595.
192. McEwan AJB, Wyeth P, Ackery DM. Radioiodinated iodobenzylguanidines for diagnosis and therapy. *Int J Appl Radia Isot* 1986; 37: 767-775.
193. Tippett PA, McEwan AJB, Ackery DM. A re-evaluation of dopamine excretion in pheochromocytoma. *Clin Endocrinol* 1986; 25: 401-410.
194. Blake GM, Zivanovic MA, McEwan AJB, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. *Eur J Nucl Med* 1986; 12: 447-454.
195. McEwan AJB, Shapiro B, Sisson JC, Beierwaltes WH, Ackery DM. Radioiodobenzylguanidine for the scintigraphic localization and therapy of adrenergic tumors. *Semin Nucl Med* 1985; 15: 132-153.
196. Paes RA, McEwan AJB, Ackery DM. Unilateral pulmonary blood flow loss in a young patient. *Nucl Med Commun* 1985; 6: 347-351.
197. Macleod MA, McEwan AJB, Pearson RR, Houston AS. Functional imaging in the early diagnosis of dysbaric osteonecrosis. *Br J Radiol* 1982; 55: 497-500.
198. Pearson RR, Macleod MA, McEwan AJB, Houston AS. Bone scintigraphy as an investigative aid for dysbaric osteonecrosis in

**PUBLICATIONS - CONTINUED**

200. Radiobiology as applied to radionuclide therapy with an emphasis on low dose rate radiation effects Murray D, Mirzayans R, McEwan AJB. In: Nuclear Medicine Therapy: Principles and Clinical Applications. Ed: C Aktolun and SJ Goldsmith, New York, 2013, pp 383-407.
201. Palliation of Bone Pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd edition. Ed: S. Gambhir and P. Ell, Churchill Livingstone, Edinburgh, 2004, pp 407-421.
202. Bone Seeking Radiopharmaceuticals to Palliate Painful Bone Metastases. McEwan AJB. In: Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. Eds: C. Bountra, R. Munglani and W. Schmidt. Marcel Dekker, Inc., New York, 2003, pp 835-855.
203. Tumor Imaging. McEwan AJB. In: Nuclear Medicine. Eds: W.D Leslie and I.D. Greenberg. Landes Bioscience, Texas, USA, 2003, pp 297-339.
204. Pain from Metastatic Bone Tumors. McEwan AJB. In: Nuclear Oncology. Ed: W.N. Tauxe and C. Aktolun, Springer-Verlag, Heidelberg, 1999, pp 245-260.
205. Synthesis, Radiochemical and Biological Evaluation of Novel ^{99m}Tc-Phosphorus-Nitrogen Complexes. Okarvi SM, Angelov CM, Cavell RG, Suresh MR, McEwan AJB. In: Technetium, rhenium and Other Metals in Chemistry and Nuclear Medicine. Eds: M Nicolini and U. Mazzi. SGE Editoriali, Italy, 1999, pp 447-455.
206. Palliation of Bone Pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, 2nd edition. Ed: I.P.C. Murray and P. Ell, Churchill Livingstone, Edinburgh, 1998, pp 1083-1099.
207. Development of a New Technetium Complex for Hypoxia Imaging: A Technetium (V) Amine Nitrophenol Complex. Zhang Z, Mannan RH, Wiebe LI, McEwan AJB. In: Technetium and Rhenium Chemistry and Nuclear Medicine, Eds: M. Nicolini, G. Bandoli and U. Mazzi, SGE Editoriali, Padova, Italy, 1995, pp 307-312.
208. Palliation of bone pain. McEwan AJB. In: Nuclear Medicine in Clinical Diagnosis and Treatment, ed: I.P.C. Murray and P. Ell, Churchill Livingstone, 1994, pp 877-892.
209. A Retrospective Analysis of the Cost Effectiveness of Treatment with Metastron in Patients with Prostate Cancer Metastatic to Bone. McEwan AJB, Amyotte GA, McGowan DG, McGillivray JA, Porter AT. In:
210. Proceedings of the 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, France June 22-24, 1994. Ed: G. Murphy, S. Khoury, C. Chatelain, L. Denis, Scientific Communications International Ltd, 1994, pp 377-385.
211. A new marker for the detection of adenocarcinomas by radioimmunosintigraphy. Noujaim AA, Sykes TR, McEwan AJB, MacLean GD, McQuarrie SA, Stanczyk G, Longenecker BM. In: Developments in Nuclear Medicine: Clinical Use of Antibodies, Tumours, infection, infarction, rejection and in the diagnosis of AIDS, ed: R.P. Baum, P.H. Cox, G. Hör and G.L. Buraggi, 1991, pp 151-168.
212. Biological Considerations in the Evaluation of Tumor-Directed Antibodies for Radioimmunosintigraphy. Sykes TR, Noujaim AA, McEwan AJB, MacLean GD. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 164-172.
213. Radioimmunosintigraphy with MAh 155 in patients with adenocarcinoma. Sykes TR, McEwan AJB, Mac TK, Borowski AI



PUBLICATIONS - CONTINUED

215. Immunoradiometric assay for the detection of circulating antibodies to murine monoclonal antibodies in humans (HAMA). Sykes CJ, Sykes TR, McEwan AJ, MacLean GD, Armstrong KJ and Noujaim AA. In: Proceedings Symposium on Radiopharmacology, ed: D.J. Maddalena, G.M. Snowdon, G.R. Boniface, 1990, pp 204-210.
216. Positron Emission Tomography and Predicting Tumor Treatment Response. McEwan AJB. In: Prediction of Tumor Treatment Response, eds: J.D. Chapman, L.J. Peters, H.R. Withers, Pergamon Press 1989, pp277-295.
217. Tumor-associated Carbohydrate Antigens as Developmentally Regulated and Prognostic Markers: A Novel Integrated Approach using Synthetic Antigens and Corresponding Monoclonal Antibodies. Longenecker BM, MacLean GD, McEwan AJB, Henningsson C, Sykes TR, Selvaraj S, Suresh MR, Noujaim AA. In: Prediction of Tumor Treatment Response, eds: J.D. Chapman, L.J. Peters, H.R. Withers, Pergamon Press 1989, pp39-64.
218. A Novel Strategy to Derive Monoclonal Antibodies for Successful Imaging of Cancer in Humans. MacLean GD, Noujaim AA, McEwan AJB, Suresh MR, Sykes TR, Marcushamer S, Longenecker BM. In: The Cellular Basis of Immune Modulation, Alan R. Liss, Inc. New York 1989, pp587-599.
219. The Potential of Synthetic Tumor-Associated Glycoconjugates (S-TAGs) for Generating Monoclonal Antibodies for Breast Cancer Imaging and for Specific Immunotherapy. MacLean GD, McEwan AJB, Mackie E, Fung P, Henningsson C, Koganty R, Madej M, Sykes T, Noujaim A, Longenecker M. In: Breast Cancer Immunodiagnosis and Immunotherapy, ed: R.L. Cerianai, Plenum Press, 1989.
220. Synthetic Thomsen Friedenreich Antigens for Production of Anti-Carcinoma Monoclonal Antibodies and Generation of Anti-Carcinoma T Cells. Longenecker BM, MacLean GD, McEwan AJB, Sykes T, Henningsson C, Suresh MR, Noujaim AA. In: Altered Glycosylation in Tumor Cells, Alan R. Liss, Inc., 1988, pp307-320.

PATENTS

Novel Compounds for Hypoxic Cell Therapy and Imaging. Wiebe LI, et al. US Provision Patent Application Serial No. 60/556,889.

INVITED LECTURES

"Ga-68 PET Imaging of NET's", Canadian Association of Nuclear Medicine (CANM) Annual Scientific Meeting, April 21-24, 2016.

"NET Therapy (MIBG and Lutetium)", Canadian Association of Nuclear Medicine (CANM) Annual Scientific Meeting, April 21-24, 2016.

"Induction and Maintenance Therapies with TRT – A New Paradigm for Treatments with Radiopharmaceuticals. Society of Nuclear Medicine June 2016.

"Lutetium-177 DOTATATE Treatment of Patients with Neuroendocrine Tumors: Driving a Hypothesis for the Biology of Radioisotope Therapy (RIT)", Laboratory Medicine & Pathology Department Rounds, April 23, 2015.

"The Role of Medical Cyclotrons in Solving the International Crisis in Technetium-99m Supply" AND "Low Dose Hypersensitivity as a Hypothesis for the Mechanism of Action of Radioisotope Therapy", World Federation of Nuclear Medicine and Biology Congress, Cancun, Mexico, August 27-31, 2014.

"Neuro-Endocrine Tumors: Canadian Centre for Excellence", Canadian Association of Nuclear Medicine, April 10 – 13, 2014.



INVITED LECTURES - CONTINUED

Grand Rounds: Treatment with the Radiolabelled Somatostatin Analog 177Lu-Dotatate for Advanced Pancreatic Neuroendocrine Tumors. McEwan AJB. March 2013.

"Current Trends in the Management of Patients with Neuroendocrine Tumours", Endocrinology Grand Rounds, St. Paul's Hospital, Vancouver, B.C., February 17, 2011

"Evolving Treatment Strategies for thyroid Cancer: A Multi Disciplinary Approach", Ted Wilkins Annual Lecture, St Pauls Hospital, Vancouver, B.C., February 17, 2011

"Evolving Treatment Strategies for Thyroid Cancer: A Multidisciplinary Approach", Al Dreydger Annual Lecture, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, April 30, 2011

"Neuroendocrine Tumours" ONIGA North and the Gastroenterology Nurses Association, Edmonton, Alberta, Miserecordia Hospital, May 24, 2011.

Radioisotope Therapy in the Management of Patients with Neuroendocrine Tumours, Western Canadian Gastrointestinal Consensus Conference, Calgary, Alberta, September 9, 2011.

A Multidisciplinary Approach to Treating Patients with Thyroid Cancer; a Nuclear Medicine Perspective, University of Laval Thyroid Symposium, Quebec City, Quebec, September 17, 2011.

The Future of Molecular Imaging in Enhancing Patient Care, European Association of Nuclear Medicine Marie Curie Lecture, Birmingham, England, October 16, 2011.

Imaging Biomarkers in the management of Patients with Cancer, Keynote Lecture, Annual Edmonton Palliative Care Conference, October 25, 2011.

Timely and Effective Diagnostic Pathways from Suspicion to Treatment, Speaker at the Provincial Family Physician Initiative, Nisku, AB, January 21, 2010.

"18F-FLT- An Imaging Biomarker That Assesses hENT Transporters of Proliferation and a roundtable on, "Tc99m Production and Availability", Society of Nuclear Medicine Annual Meeting, March 14, 2010.

Imaging Hypoxia and Potential Clinical Applications. Atis K. Freimanis Radiology Visiting Professor, Michigan State University, East Lansing, MI, March 30, 2010.

Radioisotope Therapy and Low Dose Hypersensitivity. Atis K. Freimanis Radiology Visiting Professor, Michigan State University, East Lansing, MI, March 30, 2010.

Molecular Imaging and Imaging Biomarkers. Atis K. Freimanis Radiology Visiting Professor, Michigan State University, East Lansing, MI, March 30, 2010.

Radioisotope Therapy and Low Dose Hypersensitivity. Workshop on Functional Imaging for Radiotherapy, University of British Columbia, April 8, 2010.

The State of the Art of Radionuclide Imaging and Therapy in Patients with Neuroendocrine Tumors. Keynote Speaker, American Association of Endocrine Surgeons Annual Meeting, Pittsburgh, PA, April 19, 2010.

"The State of the Art of Radionuclide Imaging and Therapy in Patients with Neuroendocrine Tumors". Presentation for the American



INVITED LECTURES - CONTINUED

"Opportunities from Translation Cancer Research in Alberta" Canadian Innovative Cancer Technologies, Canada-Taiwan Life Science Videoconference, August 4, 2010.

"Imaging Biomarkers in Advancing the Care of Patients with Cancer: The Role of an Imaging Trials Network", CIHR, Clinical Imaging Consortium Meeting, Chicago, IL, Nov 12, 2010.

"Medical Isotopes", Alberta Centre for Advanced MNT Products Seminar, Presenter and Chair of the session, Edmonton, Alberta, November 17, 2010.

"Multidisciplinary Approach to Treating Thyroid Cancer: A Nuclear Medicine Perspective", Victoria General Hospital, Victoria, BC, December 9, 2010.

Controversies in Thyroid Cancer Management. Pacific Northwest Chapter of the Society of Nuclear Medicine Annual Meeting, Tacoma Washington, March 20, 2009.

Radiopharmaceuticals in Drug Development – The Next Generation of Molecular Imaging Tests. Pacific Northwest Chapter of the Society of Nuclear Medicine Annual Meeting, Tacoma Washington, March 20, 2009.

Towards a New Functional Imaging Paradigm – Imaging Biomarkers in Clinical Practice and in Clinical Trials. British Nuclear Medicine Society Annual Meeting, Manchester, United Kingdom, April 29, 2009.

Molecular Imaging in the Management of Patients with Cancer. Chinese Society of Nuclear Medicine Annual Meeting, Changsha, China, May 17, 2009.

Cost Effective Drug Development: Specific Targets and the Role of Molecular Imaging for a Systematic Approach and a Timely Process. SNM Categorical Session: Molecular Imaging Facilitating Development of New Cancer Therapeutic Agents—Cost Effective Solution for Clinical Trials. Society of Nuclear Medicine Annual Meeting, Toronto ON, June 13, 2009.

FAZA. SNM Categorical Session: Molecular Imaging Hypoxia Biology. Society of Nuclear Medicine Annual Meeting, Toronto ON, June 13, 2009.

Introduction to the Society of Nuclear Medicine. Presentation at the Young Professionals' Committee of the SNM. Society of Nuclear Medicine Annual Meeting, Toronto ON, June 14, 2009.

Physician's Perspective. CE Session: Decision Making and Clinical Nuclear Medicine. Society of Nuclear Medicine Annual Meeting, Toronto ON, June 14, 2009.

Low Dose I-131 mIBG Therapy for Neuroblastoma. CE Session: Pediatric Neuroblastoma. Society of Nuclear Medicine Annual Meeting, Toronto ON, June 15, 2009.

Clinical Practice Guidelines and Therapy in Ablation and Follow Up—The Canadian Experience. Thyrogen Advisory Board meeting, Palm Beach FL, September 22, 2009.

Imaging Research to Clinical Outcomes: A Research Continuum. CIHR and NSERC Workshop, Vancouver BC, October 6, 2009.

Don't Underestimate the Challenges and Opportunities—Lessons Learned by the Cross Cancer Institute. Thunder Bay Regional Research Institute Retreat, Thunder Bay ON, October 15, 2009.

The Future Role of New Radiopharmaceuticals in the Management of Patients with Cancer. Canadian Association of Medical Radiation

INVITED LECTURES - CONTINUED

Experience with mIBG. Nuclear Oncology: From Genotype to Phenotype to Targeted Therapy. Johns Hopkins Continuing Medical Education, Baltimore, MD, March 14, 2008.

Metastatic Bone Disease. Nuclear Oncology: From Genotype to Phenotype to Targeted Therapy. Johns Hopkins Continuing Medical Education, Baltimore, MD, March 15, 2008.

Molecular Imaging and Its Contribution to Cancer Care and Drug Development. Nuclear Medicine Tomorrow Conference, Nantes, France, March 31, 2008.

Management of Patients with Thyroid Cancer: Experience at the Cross Cancer Institute. Thyroid Rounds. Calgary, Alberta, April 9, 2008.

Imaging in Palliative Care and Future Prospects. Palliative Care Rounds, Edmonton, Alberta, April 18, 2008.

Highlights and Future Look at Nuclear Medicine. British Nuclear Medicine Society Annual Meeting, Edinburgh Scotland, May 14, 2008.

PET/CT and Molecular Imaging in Medical Practice. China Molecular Imaging Strategic Summit, Beijing, China. May 17, 2008.

Introduction of PET/CT and Molecular Imaging in Medical Practice. China Molecular Imaging Strategic Summit, Beijing, China. May 17, 2008.

Molecular Imaging and Cancer: Optimizing Clinical Trials and Clinical Practice--A Joint ASCO/Society of Nuclear Medicine (SNM) Education Session. ASCO, Chicago IL, June 1, 2008.

Imaging Biomarkers and Molecular Medicine: From Molecule to Treatment. 3rd Annual London Imaging Discovery Day. London, ON, June 5, 2008.

Overview of the Concept and Potential Targets – Opportunities for Molecular Imaging and Therapy. Categorical Seminar: Molecular Image Guided Cancer Therapy: Towards Personalized Treatment – Moving Away from "One Size Fits All" Concept. Society of Nuclear Medicine Annual Meeting, New Orleans, LA, June 14, 2008.

Molecular Imaging in the Management of Patients with Cancer. RADaim Meeting, Gold Coast, Australia, July 25, 2008.

Molecular Imaging in the Era of Molecular Medicine: Challenges and Opportunities. RADaim Meeting, Gold Coast, Australia, July 26, 2008.

Current Status and Postulated Radiobiology of I-131 mIBG Therapy. RADaim Meeting, Gold Coast, Australia, July 26, 2008.

Radioisotopes in Cancer Diagnosis and Therapy. University of Pennsylvania - Pfizer Visiting Professor in Oncology. September 29, 2008.

Radiolabelled Probes in Clinical Practice, Clinical Research and Drug Development. ACRIN Experimental Sciences Imaging Committee, Pentagon City, VA. October 4, 2008

Molybdenum-99, Clinical Practice and a Crisis of Supply. Task Force on Alternatives for Medical-Isotope Production. TRIUMF, Vancouver, British Columbia. October 19, 2008.

Breast Cancer Imaging. Positively Pink Breast Cancer Public Education Day, Edmonton, Alberta, October 26, 2008.

INVITED LECTURES - CONTINUED

Integration of Imaging Biomarkers into Drug Development and Clinical Practice. The 2nd Alberta Cancer Research Institute Annual Research Meeting, Banff, Alberta, November 27, 2008.

Molecular Imaging of Hypoxia: 18F-Fluoroazomycin Arabinoside (FAZA). IBA Molecular Medical Advisory Board. Louvain la Neuve, Belgium, February 2, 2007.

Update on New Therapeutic Agents. Los Angeles Radiological Society and Pacific Southwest Chapter of the Society of Nuclear Medicine Nuclear Medicine Update 2007 meeting, Los Angeles, California, April 21, 2007.

How Functional and Molecular Imaging Will Contribute to Patient Care in Cancer and Neurology. Alberta College of Medical Diagnostic and Therapeutic Technologies Conference, Edmonton Alberta, April 27, 2007.

Future Perspectives on PET and Molecular Imaging in the Management of Patients with Cancer. Canadian Society of Nuclear Medicine Annual Meeting, St. John's, Newfoundland, May 5, 2007.

Low Dose I-131 mIBG Therapy of Neuroblastoma. In Categorical Seminar: Radiopharmaceutical Therapy in Pediatrics. Society of Nuclear Medicine Annual Meeting, Washington DC, June 2, 2007.

Molecular Imaging of Cancer Using NM. In Categorical Seminar: Molecular Imaging and Cancer Therapy: Opportunities and Challenges for Nuclear Medicine. Society of Nuclear Medicine Annual Meeting, Washington DC, June 2, 2007.

Current Status and Future Prospects of I-131 mIBG Therapy. In Continuing Medical Education session: The Role of MIBG in the Diagnosis and Treatment of Neuroendocrine Tumors. Society of Nuclear Medicine Annual Meeting, Washington DC, June 4, 2007.

Lessons from Canada—The Radiology Report of the Future. 2007 Intersociety Conference, Annapolis, Maryland, July 28, 2007.

Future of PET and Molecular Imaging in Oncology. National Conference on Oncology, Chinese Society of Nuclear Medicine, Urumchi, China, August 11, 2007.

Current Contributions on the Radiobiology of Radioisotope Therapy. National Conference on Oncology, Chinese Society of Nuclear Medicine, Urumchi, China, August 11, 2007.

Current and Future Roles of PET/CT in Oncology Practice. Rounds, Beijing Hospital, Beijing, China, August 17, 2007.

Future of PET and Molecular Imaging in Oncology. Lecture, Beijing Hospital, Beijing, China, August 17, 2007.

Hypoxia Imaging. 2007 ASTRO Translational Research in Radiation Oncology and Radiology Symposium, San Francisco CA, September 8, 2007.

Molecular Imaging. WPO Focus Forum Meeting, Lake Louise AB, September 23, 2007.

Current Role of Radiopharmaceuticals in Neuroendocrine Tumors. Neuroendocrine Disease Oriented Group for NCIC Clinical Trials Group. Toronto ON, October 30, 2007.

2007 ACB Annual Research Meeting: Quo Vadis ACB Research. Alberta Cancer Board Annual Research Meeting, Banff AB, Nov 8, 2007.

PET in Oncology. International Conference on Application of Radiotracers in Chemical, Environmental and Biological Sciences, Kolkata, India, January 27, 2006.



INVITED LECTURES - CONTINUED

Hypoxia Imaging. University of Cambridge, School of Clinical Medicine Wednesday Forum, Cambridge, United Kingdom, May 9, 2006.

How Can the Nuclear Medicine Community Interact with the Roadmap? Society of Nuclear Medicine Annual Meeting, Categorical on Molecular Imaging and Therapy and the NIH Roadmap: Perspectives and Potential, San Diego, CA, June 3, 2006.

New Trends in Treatment of Neuroendocrine Tumors. Society of Nuclear Medicine Annual Meeting, Continuing Education on Neuroendocrine Tumors, San Diego, CA, June 4, 2006.

mIBG Therapy. Society of Nuclear Medicine Annual Meeting, Continuing Education on mIBG Therapy, San Diego, CA, June 6, 2006.

Molecular Imaging in the Era of Molecular Medicine: How Do We Get From Here to There? British Nuclear Medicine Society Autumn Scientific Meeting, Cambridge, UK, September 4, 2006.

Trial Design to Validate F-18 Quantification. PET and Molecular Imaging Symposium, Philadelphia PA, October 16, 2006.

Hypoxia and Hypoxic Imaging Agents. PET and Molecular Imaging Symposium, Philadelphia PA, October 16, 2006.

Appropriate Outcome Measures to Validate Imaging Biomarkers. PET and Molecular Imaging Symposium, Philadelphia PA, October 16, 2006.

Nuclear Medicine, Molecular Imaging and Personalized Medicine: Opportunities and Pitfalls. Society of Nuclear Medicine Eastern Great Lakes Chapter Annual Meeting, Oakville ON, October 19, 2006.

An Overview of Radiobiology and Clinical Utilization of Radioisotope Therapy. Society of Nuclear Medicine Eastern Great Lakes Chapter Annual Meeting, Oakville ON, October 19, 2006.

Imaging Cell Death and Signaling Network. World Federation of Nuclear Medicine and Biology, Session CS1A Molecular Imaging, Seoul, Korea, October 22, 2006.

Therapeutic Radiolabelled Antibody. World Federation of Nuclear Medicine and Biology, Session TCS1 Radiolabelled Antibody, Seoul, Korea, October 22, 2006.

Catching Cancer Early—What's New in Diagnostic Imaging? Hereditary Breast and Ovarian Cancer Society of Alberta 5th Annual Fall Conference, Edmonton AB, November 4, 2006.

Future Directions in PET Imaging in Cancer Management. 2006 Alberta Cancer Board Annual Research Meeting, November 9, 2006.

PET Imaging in Gastroenterology. GI Rounds, University of Alberta Hospital, Edmonton Alberta, February 14, 2005.

PET Scanning. Alberta Chapter of the American College of Surgeons Annual Meeting, Banff, Alberta, February 19, 2005.

Overview of the Use of PET in Oncology. CME Recent Advances in Nuclear Oncology Kuwait Institute for Medical Specialization, Faculty of Nuclear Medicine, Kuwait University, Jabriya, Kuwait, March 14, 2005.

Hypoxia Imaging: Introduction and Overview of Future Applications. CME Recent Advances in Nuclear Oncology Kuwait Institute for Medical Specialization, Faculty of Nuclear Medicine, Kuwait University, Jabriya, Kuwait, March 14, 2005.

Low-Dose I-131 mIBG Therapy in Neuroblastoma: Radiobiological Justifications and Clinical Outcomes. Children's Oncology Group



INVITED LECTURES - CONTINUED

Adult Neuroendocrine Tumors: Current State of the Art in Clinical Management. mIBG Workshop, Molecular Insight Pharmaceuticals Inc. Washington DC, August 4-5, 2005

Do We Understand the Biology and Clinical Applicability of Radioisotope Therapy? Invited Grand Rounds, London Health Sciences Centre, London ON, September 20, 2005

Imaging Hypoxia—Pitfalls and Opportunities. Program Rounds Presentation, Princess Margaret Hospital, Toronto ON, September 21, 2005.

Advances in Radioisotope Therapy. Kuwait Institute for Medical Specialization, Kuwait City, Kuwait, November 15, 2005.

Current Concepts in the Radiobiology of Radioisotope Therapy. International Atomic Energy Agency International Symposium on Nuclear Oncology, Porto Alegre, Brazil, January 20, 2004.

Treatment of Metastatic Bone Pain. International Atomic Energy Agency International Symposium on Nuclear Oncology, Porto Alegre, Brazil, January 23, 2004.

Outcomes Analysis—How We Should Measure Efficacy of Target Radiopharmaceutical Therapy. Society of Nuclear Medicine Mid-Winter Meeting, Anaheim, California, February 8, 2004.

Introduction to the Practice of Radioisotope Therapy. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 16, 2004.

Radioisotope Management of Symptomatic Bone Disease. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 16, 2004.

Radioisotope Management of Neuroendocrine Tumors. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 17, 2004.

New Concepts in the Radiobiology of Radioisotope Therapy. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 17, 2004.

PET To Follow-Up on Treatment Response. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 18, 2004.

Contribution of Nuclear Medicine to Oncological Practice. Kuwait Institute for Medical Specialization, CME Course: Update on PET and Nuclear Oncology, Kuwait City, Kuwait, February 18, 2004.

Illustrating the Potential: A New Therapeutic Radiopharmaceutical. Session 2B Radiopharmaceutical Research at Canadian Society of Nuclear Medicine Meeting, Niagara-on-the-Lake, Ontario. April 22, 2004.

World Wide Introduction. Session 7 Evidence-Based Practice in Diagnostic Imaging at Canadian Society of Nuclear Medicine Meeting, Niagara-on-the-Lake, Ontario. April 24, 2004.

Molecular Imaging, Radiobiology, Radioisotope Therapy—Where is the Common Ground? Rounds, University of Washington at Seattle, May 13, 2004.

Trial Design and Outcome Measurements in Radioisotope Therapy—Implications for Clinical Outcome Based on the New Science of

INVITED LECTURES - CONTINUED

A Practical Introduction to PET Imaging. Rounds, Grey Nuns Hospital, Edmonton AB, September 28, 2004.

Current Practice in Bone Pain Palliation with Radioisotope Therapy. Presidential Course on Metastatic Disease, The American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting, Atlanta GA, October 3, 2004.

Innovations in Technology: Positron Emission Tomography. 2004 Lil Faider Lecture Series, Canadian Cancer Society, Tom Baker Cancer Centre, Calgary, Alberta, October 7, 2004.

Radionuclide Therapy of Metastatic Bone Pain. Special Lecture to the 44th Annual Meeting of the Japanese Society of Nuclear Medicine, Kyoto, Japan, November 5, 2004.

PET Imaging for Oncology. Berlex Educational Forum, Vancouver, British Columbia, November 27, 2004.

New Perspectives in Radioisotope Therapy. Berlex Educational Forum, Vancouver, British Columbia, November 27, 2004.

Approach to PET in Alberta, Contrasting with the Ontario Approach. Ontario PET Steering Committee Retreat, Toronto, Ontario, December 1, 2004.

Radiation and Imaging. The Expanding Role of Octreotide in Oncology Symposium, Mont Tremblant, Quebec, January 24, 2003.

PET Imaging in Lung Cancer: Its Role and Potential Application. Grand Oncology Rounds, Tom Baker Cancer Centre, Calgary, Alberta, February 26, 2003.

Nuclear Oncology—An Overview. Visiting Professor, University of Calgary, Calgary, Alberta, February 26, 2003.

Molecular Imaging—Establishing a Programme. Current Uses and Future Prospects, Visiting Professor, University of Calgary, Calgary, Alberta, February 27, 2003.

Radioisotope Therapy in Neuroendocrine Cancer. Radiation Oncology Resident Seminar, University of Calgary, Calgary, Alberta, April 8, 2003.

PET Imaging in Oncology. Radiation Oncology Resident Seminar, University of Calgary, Calgary, Alberta, April 8, 2003.

Radioisotope Therapy. Canadian Society of Nuclear Medicine Annual Meeting, Halifax, Nova Scotia, May 9, 2003.

I-131 mIBG Therapy of Neuroendocrine Tumors—Lessons for a New Clinical Approach to Radioisotope Therapy. Society of Nuclear Medicine Annual Meeting. Current and Future Prospects in Radioisotope Therapy. New Orleans, Louisiana, June 21, 2003.

The Future of Nuclear Medicine: PET Research and Radioisotope Therapy. Presentation to Biologics and Genetic Therapies Directorate of Health Canada, Ottawa, Ontario, July 9, 2003.

Challenges in Expanding Radioisotope Therapy. Targeted Molecular Therapy Workshop, U.S. Department of Energy, Bethesda MD, July 14, 2003.

Principles and Practice of Radioisotope Therapy: From Clinical Trials to New Paradigms in Radiobiology. E.S. Garnett Lecture, McMaster University, Hamilton, Ontario, October 20, 2003.

Principles and Practice of Radioisotope Therapy. Lymphoma Rounds, Hamilton Health Sciences Centre, Hamilton, Ontario, October 21,



INVITED LECTURES - CONTINUED

Radioisotope Therapy: From Radiobiology to Practical Outcomes. Memorial Sloan Kettering Cancer Centre, New York, NY, December 1, 2003.

PET Scanning in Breast Cancer at the Cross Cancer Institute. Joint Presentation with Dr. K. Tonkin. Grand Rounds, Cross Cancer Institute, Edmonton, Alberta February 26, 2002.

Relieving Metastatic Bone Pain. Targeted Radionuclide Therapy Course, Johns Hopkins University School of Medicine, Baltimore, Maryland, March 15, 2002.

Peptide Radiotherapy. Targeted Radionuclide Therapy Course, Johns Hopkins University School of Medicine, Baltimore, Maryland, March 15, 2002.

Neuroblastoma and Pheochromocytoma. Targeted Radionuclide Therapy Course, Johns Hopkins University School of Medicine, Baltimore, Maryland, March 16, 2002.

Radionuclide Therapeutics. Eastern Great Lakes Chapter of the Society of Nuclear Medicine, 22nd Annual Meeting, Buffalo, NY, March 22, 2002.

Potential of Hypoxia Imaging to Impact Patient Management. Eastern Great Lakes Chapter of the Society of Nuclear Medicine, 22nd Annual Meeting, Buffalo, NY, March 22, 2002.

Establishing PET in Western Canada—Development of a Regional Model. Joint Presentation with Dr. S. A. McQuarrie, Canadian Society of Nuclear Medicine Annual Meeting, Edmonton, Alberta, April 5, 2002.

Bone Pain Palliation. Canadian Society of Nuclear Medicine Annual Meeting, Edmonton, Alberta, April 7, 2002.

PET Scanning in Oncology. Alberta Society of Melanoma Meeting, Cross Cancer Institute, Edmonton, Alberta, April 13, 2002.

Radioisotope Therapy—Trial Design for Alpha Particle Therapy. Lessons from Beta Particles. Alpha Therapy Workshop, TRIUMF, Vancouver, BC, April 29, 2002.

PET Imaging for Cancer. Invited Presentation to the Standing Policy Committee, Alberta Legislature, Edmonton, Alberta, April 29, 2002.

Overview of Radioisotope Therapy. Seminar Presentation at NeoRx Corporation, Seattle, WA, May 7, 2002.

PET Scanning in Patients with Lung Cancer. Thoracic Surgery Program Development Retreat, Edmonton, AB, June 1, 2002.

NMTOG and Radioisotope Therapy Clinical Trials Cost/Benefit Analysis for the SNM. Presentation to Clinical Trials Council at Society of Nuclear Medicine Annual Meeting, Los Angeles, California, June 15, 2002.

Radiopharmaceutical Therapy: Patient Management Issues. Lecture at CME Session: Targeted Radiopharmaceutical Therapy: Issues for the Nuclear Medicine Community. Society of Nuclear Medicine Annual Meeting, Los Angeles, California, June 18, 2002.

Radioisotope Therapy: Current Role and Future Perspectives. Medicina Nucleare e terapia: Applicazioni consolidate e nuovi orizzonti. Italian Society of Nuclear Medicine Meeting, Legnano, Italy, October 11, 2002.

PET Imaging in Lung Cancer. Symposium on Current Trends in Lung Cancer, Toronto, Ontario, November 28, 2002.



INVITED LECTURES - CONTINUED

PET: Molecular Imaging for the 21st Century. Presented to University of Alberta Chapter of the Alpha Omega Alpha Meeting, Edmonton, Alberta, January 31, 2001.

Overview of I-131 mIBG Therapy in Neuroendocrine Tumors. Special Rounds, Peter MacCallum Cancer Institute, Melbourne, Australia, March 22, 2001.

ERC9: A New Diagnostic and Therapeutic Radiopharmaceutical in Patients with Melanoma. Special Rounds, Peter MacCallum Cancer Institute, Melbourne, Australia, March 28, 2001.

Therapeutic Nuclear Medicine: Its Role and Indication. Presented to the Ontario Medical Association Section on Nuclear Medicine Annual General Meeting, Toronto, April 26, 2001.

Status of Nuclear Medicine in Canada. Presented to the Ontario Medical Association Section on Nuclear Medicine Annual General Meeting (Business Meeting), Toronto, April 26, 2001.

PET Concepts and the Future Availability of PET in Canada. Presented to the Canadian Association of Medical Radiation Technologists 2001 Conference, Regina, Saskatchewan, June 12, 2001.

Therapeutic/Palliative Nuclear Medicine. Presented to the Canadian Association of Medical Radiation Technologists 2001 Conference, Regina, Saskatchewan, June 12, 2001.

Cancer Imaging: Present and Future. Joint presentation with Dr. R. Hennig to Cancer Care in the Millennium, Edmonton, Alberta, June 15, 2001.

PET Imaging in Canada and Its Role in Cancer Imaging. Public Awareness Forum, Mount Sinai Hospital, Toronto, Ontario, June 23, 2001.

Establishing a Radioisotope Therapy Programme. Society of Nuclear Medicine 48th Annual Meeting, CME Session "Establishing a Referral Base for PET and Radioisotope Therapy", Toronto, Ontario, June 25, 2001.

Shortages of Diagnostic Imaging Equipment and Technicians. Ontario Hospital Association Conference for Board Chairs and Vice Chairs, Toronto, Ontario, September 24, 2001.

Radioisotope Therapy in the Management of Neuroendocrine Tumors. 26th Annual Western Regional Meeting of the Society of Nuclear Medicine, Vancouver, British Columbia, October 13, 2001.

Positron Emission Tomography in Patients with Breast Cancer. Canadian Breast Cancer Foundation National Annual General Meeting, Edmonton, Alberta, November 4, 2001.

Hypoxia Imaging. Canadian Society of Nuclear Medicine/Canadian Association of Nuclear Medicine Annual Meeting, Montebello, Quebec, November 10, 2001.

The Edmonton PET Programme. Special City-Wide Rounds, Cross Cancer Institute, Edmonton, March 22, 2000.

Radionuclide Therapy and Symptom Palliation. Continuing Medical Education Presentation, Canadian Society of Nuclear Medicine Meeting, Mont Tremblant, P.Q., April 1, 2000.

Radionuclide Therapy of Painful Metastases to Bone. Presented in: Radionuclide Therapy: Old Concepts and New Approaches, Department of Veterans Affairs Employee Education System/VA Nuclear Medicine and Radiation Safety Service Television Broadcast



INVITED LECTURES - CONTINUED

Future Prospects in Therapeutic Nuclear Medicine—What Have we Learned from mIBG and Where are Peptides Taking Us. Special Lecture Pakistan Institute of Engineering and Applied Science, Islamabad, Pakistan, August 3, 2000.

Functional Imaging: From Hypoxia to Gene Therapy. Special Lecture Pakistan Institute of Engineering and Applied Science, Islamabad, Pakistan, August 3, 2000.

Phase II Study of Iodine-123 Radioiodinated N[3-(4-Morpholino)-Propyl]-N-Methyl-2-Hydroxy-3-Methyl-5-Iodobenzylamine (ERC9) in Evaluating Patients with Melanoma. Presented at the Prairie Provinces Chapter of the Society of Nuclear Medicine Meeting, Edmonton, Alberta, September 22-23, 2000.

Phase I Study of 111In Octreotide Therapy in Patients with Neuroendocrine Tumors. Presented at the Prairie Provinces Chapter of the Society of Nuclear Medicine Meeting, Edmonton, Alberta, September 22-23, 2000.

Neuroendocrine Tumor Imaging with 123I mIBG versus 111In Octreotide. Presented at the Prairie Provinces Chapter of the Society of Nuclear Medicine Meeting, Edmonton, Alberta, September 22-23, 2000.

I-131 mIBG Therapy in Pheochromocytoma: Experience with a Multiple Dose Regimen. Presented at the Prairie Provinces Chapter of the Society of Nuclear Medicine Meeting, Edmonton, Alberta, September 22-23, 2000.

The Effect of Thyroid Gland Stunning by I-131 Sodium Iodide Diagnostic Scans on Subsequent Patient Ablation Doses—A 25 Year Retrospective Study. Presented at the Prairie Provinces Chapter of the Society of Nuclear Medicine Meeting, Edmonton, Alberta, September 22-23, 2000.

Experience of PET in Western Canada. ADAC Users Group Meeting, Toronto, Ontario, November 4, 2000.

Introduction to Session Oncology Application for Radioisotopes: Systemic Imaging Therapy. Presented at Advances in Use of Radioisotopes Meeting, Washington DC, March 11-13, 1999.

Innovations in Imaging. Presented at University of Alberta Continuing Medical Education Session: Internal Medicine for Primary Care Physicians, Edmonton, Alberta, April 23-24, 1999.

Radioisotopes for Medical Therapy—Prospects for the Future. Presented at The Third International Conference on Isotopes, Vancouver, British Columbia, September 6-10, 1999.

Radioisotope Therapy—Past, Present, and Hopes and Needs for the Future. Grand Rounds, Cross Cancer Institute, Edmonton, September 14, 1999.

Cancer Therapies. Presented to the Prostate Cancer Support Group, Cross Cancer Institute, Edmonton, September 14, 1999.

What's New in Nuclear Medicine? An Update for General Surgeons. Presented to Department of Surgery Grand Rounds, Faculty of Medicine, University of Alberta, Edmonton, December 10, 1999.

Imaging Hypoxia with I-123 IAZA. Grand Rounds, Cross Cancer Institute, Edmonton, February 3, 1998.

Scintigraphic Assessment of Gene Expression in Gene Therapy of Cancer. Society of Nuclear Medicine Prairie Provinces Chapter Meeting, Saskatoon, April 3, 1998.

Pain Treatment in Metastases - Metastron® (Strontium Chloride). Keynote lecture, Taiwanese Society of Nuclear Medicine, Taipei,

**INVITED LECTURES - CONTINUED**

Localization and Therapeutic Treatment of Carcinoid Syndrome with Nuclear Pharmacological Agents. Presented at the University of Calgary Carcinoid Symposium, Calgary, AB, November 20, 1998.

mIBG Therapy for Carcinoid. Medical Oncology Rounds, CCI, January 27, 1997.

Nuclear Medicine Therapy. Mallinckrodt Medical Nuclear Working Group, St. Louis, MI, April 25, 1997.

Radionuclide Therapy for Palliation of Painful Skeletal Metastases. CME Advances in Internal Medicine Course, University of Michigan, Ann Arbor, MI, April 30, 1997.

Imaging Hypoxia with a Novel Single Photon Radiopharmaceutical. Invited Grand Rounds University of Michigan, Ann Arbor, MI, May 1, 1997.

Breast Cancer Imaging with Radiolabeled MAbs. 18th Annual Eastern Great Lakes Chapter of the Society of Nuclear Medicine, Toronto, May 2, 1997.

Isotope Therapies. 18th Annual Eastern Great Lakes Chapter of the Society of Nuclear Medicine, Toronto, May 2, 1997.

Role of mIBG in the Management of Neuroblastoma. The Canadian Society of Diagnostic Medical Sonographers Spring Conference and Annual General Meeting, Edmonton, May 29, 1997.

An Overview of Strontium-89 Clinical Investigation and Practice Related Issues. Presented at the CME Course "Radionuclide Therapy of Bone and Joint Diseases", Society of Nuclear Medicine Meeting, San Antonio, Texas, June 1, 1997.

Pheochromocytomas and Neuroblastoma. Actualizaciones Oncológicas con Medicina Nuclear, Santiago, Chile, June 20-21, 1997.

Neuroendocrine Tumours. Actualizaciones Oncológicas con Medicina Nuclear, Santiago, Chile, June 20-21, 1997.

Nephrourologic Tumours. Actualizaciones Oncológicas con Medicina Nuclear, Santiago, Chile, June 20-21, 1997.

F18 Deoxyglucose in Oncology Perspectives. Actualizaciones Oncológicas con Medicina Nuclear, Santiago, Chile, June 20-21, 1997.

Bone Pain Therapy in Metastatic Disease. Actualizaciones Oncológicas con Medicina Nuclear, Santiago, Chile, June 20-21, 1997.

Unsealed Source Radiopharmaceutical Therapy. Oncology Centre, Ekaterinburg, Russia, September 25, 1997.

Pain Palliation in Cancer, Radiology Centre, St. Petersburg, Russia, September 26, 1997.

New Concepts in Imaging Melanoma. Alberta Society of Melanoma, Edmonton, October 25, 1997.

I-131 mIBG: Review of Current Literature. Canadian Association of Nuclear Medicine/Society of Nuclear Medicine (Canada) Conjoint Scientific Meeting, Ottawa, November 9-12, 1997.

Radiotherapy in Management of Patients with Prostate Cancer. 29th Annual Conference of the Indian Society of Nuclear Medicine Inauguration, Chandigarh, India, November 16, 1997.

Palliation of Pain in Cancer Metastatic to Bone: Clinical Use of Metastron (89SrCl). 29th Annual Conference of the Indian Society of Nuclear Medicine -- Oncology Day, Chandigarh, India, November 17, 1997.



INVITED LECTURES - CONTINUED

Pain Treatment in Bone Metastases - Metastron. Mexico City, Mexico. Two presentations, November 28, 1997

I-131 mIBG Therapy--A Review of the CCI Experience. Grand Rounds, Cross Cancer Institute, Edmonton, December 9, 1997.

Strontium-89 (Metastron) to Treat Cancer Metastatic to Bone. Lectures to Medical Communities in Madras, Calcutta, Bombay and Delhi, India, January 21-24, 1996.

Strontium-89 Therapy for Palliation of Pain in Prostate Cancer Metastatic to Bone. Prostate Cancer Support Group, Cross Cancer Institute, February 13, 1996.

Metastron: Pain Palliation in Cancer Metastatic to Bone - The Clinical Role of Therapy with Metastron. Strontium-89 lectures in Lahore and Karachi, Pakistan, April 24 and 25, 1996.

Palliation in Cancer Metastatic to Bone - The Clinical Role of Therapy with Metastron (89Sr Cl). Strontium-89 lectures, Taipei, Taiwan, May 13-15, 1996

Palliation in Cancer Metastatic to Bone - The Clinical Role of Therapy with Metastron (89Sr Cl). Strontium-89 lectures, Seoul, Korea, May 16-17, 1996. Abstract published in Korean J Nucl Med 1996; 30, 2: 158.

Medical Aspects of Cancer. Prostate Cancer Support Group, Cross Cancer Institute, September 10, 1996.

Imaging Tumor and Tissue Hypoxia. Second International Radiopharmaceutical Therapy Colloquium, Kyoto, Japan. Presented September 30, 1996.

Radiopharmaceutical Unsealed Source Therapy: Past, Present and Future. 1996 Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec. Presented October 23, 1996.

Octreotide Imaging -- A Review. St. Paul's Hospital, Vancouver, BC, November 22, 1996.

Strontium-89 in the Palliation of Pain from Metastatic Bone Disease from Breast and Prostate Cancers. Presentation to the Seoul Nuclear Medicine Community, Seoul, and Metastron Seminar, Busan, Korea, January, 1995.

Receptor Imaging in Nuclear Medicine. Capital Region Nuclear Medicine Society, Ottawa, Ontario, March, 1995.

Somatostatin Analogue Receptor Imaging - The Holy Grail? Southern California Chapter of the Society of Nuclear Medicine 1995 Benedict Cassen Memorial Symposium, Long Beach, CA, March, 1995.

Novel Radiopharmaceutical Therapies - Are We Moving Forward?? Southern California Chapter of the Society of Nuclear Medicine 1995 Benedict Cassen Memorial Symposium, Long Beach, CA, March, 1995.

Radioimmunosintigraphy with Radiolabelled Monoclonal Antibodies Reactive with Adenocarcinoma and Squamous Cell Carcinoma. Toronto Nuclear Medicine Society, Toronto, Ontario, March, 1995.

Pain Palliation in Metastatic Bone Disease. German Society of Nuclear Medicine, Dresden, Germany, March, 1995.

Experimental Design in Study of Pain Relief; Strontium-89 Therapy for Painful Bone Metastases. Annual Categorical Course on Painful Bone Metastases - The Role of Beta Emitting Radiopharmaceuticals at the Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis, Minnesota, July, 1995.

**INVITED LECTURES - CONTINUED**

A Radiolabelled Hypoxic Marker--Preliminary Data Defining Possible Clinical Use. Rambam Medical Centre Rounds, Haifa, Israel, January, 1994.

In-Vivo Mechanisms in the Palliation of Bone Pain in Cancer Patients. Society of Nuclear Medicine Pacific Northwest Chapter Symposium on Radionuclide Therapy of Painful Bone Metastases: Current Status and Future Prospects. Seattle, Washington, February, 1994.

Octreotide Imaging: An Introduction and Review. Nuclear Medicine Canada '94, Banff, Alberta, March, 1994.

Imaging with In-111 Octreotide--A Review. Grand Rounds, Vancouver General Hospital, May 3, 1994.

Bone Pain Therapy. Annual Categorical Course on Therapy with Unsealed Sources, Society of Nuclear Medicine 41st Annual Meeting, Orlando, Florida, June 4, 1994.

What price quality of life -- a cost benefit analysis of 'Metastron' (Strontium 89 Chloride). 4th International Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment, Paris, France, June, 1994.

Palliation of Pain with Beta Emitting Radiopharmaceuticals. International Symposium on Quality Assurance and Quality Control, Washington, D.C., September, 1994.

Palliative Therapy of Painful Bone Metastases with Strontium-89: A Review. Invited Grand Rounds, Tom Baker Cancer Centre and Foothills Hospital, Calgary, Alberta, September 21, 1994.

Strontium-89 Therapy for Bone Pain. Symposium: Maladie Métastatiques: Applications Cliniques et Pratiques du Chlorure de Strontium-89, Hôtel-Dieu de Montréal, Montréal, Quebec, November 16, 1994.

Medical Aspects of Cancer. CanSurmount Visitor Training Session, Edmonton, AB, October, 1994.

External Beam Therapy of Bone Metastases. Painful Bone Metastases: A Tutorial on Palliation, Rockville, Maryland, April, 1993.

Sr-89 Treatment for Painful Skeletal Metastases. Fourth Western Regional Hawaii Meeting of the Society of Nuclear Medicine, Maui, Hawaii, May, 1993.

External Beam Therapy of Bone Metastases. Course on Painful Bone Metastases: A Tutorial on Palliation at the Society of Nuclear Medicine 40th Annual Meeting, Toronto, Ontario, June, 1993.

The Trans-Canada Phase III Trial of Strontium-89 Chloride in Stage D Prostate Cancer. Implications for Quality of Life and Economics of Patient Management. European Cancer Centre, Amsterdam, The Netherlands, October, 1993.

The Clinical Role of Strontium-89 in the Management of Patients with Painful Bone Metastases, Hertogenbosch, The Netherlands, October, 1993.

Strontium-89 -- An Overview and Cost Benefit Analysis. Amsterdam, The Netherlands, October, 1993.

Palliation of Bone Metastases with 89Sr Chloride. For Continuing Education Course "Therapeutic Nuclear Medicine--What are the Prospects?" at Michener Institute, Toronto, Ontario, October, 1993.

Review of Role of Strontium-89 in Clinical Practice. The University of Michigan Medical Center, Ann Arbor, Michigan, December, 1993.

INVITED LECTURES - CONTINUED

HMPAO Brain Imaging in Psychiatric Diseases, Mental Health Research Institute, Melbourne, Australia, February, 1992.

Strontium-89 Therapy--A Review of Clinical Trials Data, Medi-Physics Innovations in Oncology Advisory Board, Chicago, Illinois, May, 1992.

Strontium-89 Therapy: A Review of the Results of the Trans-Canada Collaborative Study, Strontium-89 Users Group Meeting, Los Angeles, California, June, 1992.

Ceretec, Tc-99m HMPAO Functional Imaging. Foothills Hospital, Calgary, Alberta, June, 1992.

Quantification of HMPAO. In Session on "Functional Brain Imaging", Royal College of Physician and Surgeons of Canada Annual Meeting, Ottawa, Ontario, September, 1992.

mIBG Therapy. In Session on "Radionuclide Therapy of Malignant Disease", Royal College of Physician and Surgeons of Canada Annual Meeting, Ottawa, Ontario, September, 1992.

Strontium-89 to Palliate Bone Pain in Cancer Metastatic to Bone. Department of Radiology, McMaster University, Hamilton, Ontario, November, 1992.

Novel Radiopharmaceuticals in the Evaluation of Patients with Cancer. Radiology Research Day, McMaster University, Hamilton, Ontario, November, 1992.

Radiological Research: The Past and the Future. Radiology Research Day, McMaster University, Hamilton, Ontario, November, 1992.

Nuclear Oncology--The Future. Institute of Nuclear Medicine and Oncology, Lahore, Pakistan, November, 1992.

Treatment of Patients with Malignant Phaeochromocytoma with I-131 Meta Iodobenzylguanidine (mIBG). International Workshop on 131I mIBG Therapy, Rome, Italy, September, 1991.

Treatment of Patients with Metastatic Carcinoid Tumor with I-131 Meta Iodobenzylguanidine (mIBG). International Workshop on 131I mIBG Therapy, Rome, Italy, September, 1991.

HMPAO Brain Imaging and Fitting. Northwest Conference of Radiologic Technologists Meeting, Edmonton, Alberta, September, 1991.

Endocrine Tumor Localization, British Institute of Radiology Annual Meeting, June, 1990.

Strontium-89 Therapy, 5th World Congress of Nuclear Medicine and Biology, Montreal, August, 1990

Strontium-89 Palliative Treatment for Bone Pain. Cancer Care: The Complete Circle, Edmonton, Alberta, November, 1990.

¹⁵³Sm EDTMP therapy in patients with prostate cancer metastatic to bone. European Association of Nuclear Medicine Annual Meeting, May, 1990.

Strontium-89 in the treatment of bone pain in patients with metastatic prostate cancer. The Prairie Urological Association Meeting, Lake Louise, February 21, 1987.

Strontium-89 in the treatment of metastatic prostate cancer. Third Western Regional Spring Meeting, Society of Nuclear Medicine, Hawaii, April 25-29, 1987.



INVITED LECTURES - CONTINUED

131I meta iodobenzylguanidine: clinical applications. British Nuclear Medicine Society Annual Meeting, April 1986.

131I mIBG in neuroblastoma: The Southampton Experience. 4th International Workshop in Paediatric Oncology, Rome, September, 1986.

131I meta-iodobenzylguanidine in the management of tumors of neural crest origin. Royal Society of Medicine, Radiology Section Annual Meeting, October 1985.

Radioiodinated iodobenzylguanidine for the treatment of neuroblastoma. United Kingdom Child Cancer Study Group Annual Scientific Meeting, November 1985.

131I mIBG for the localization of pheochromocytoma. British Institute of Radiology Wessex Region Annual Meeting, November, 1985.

ABSTRACTS AND PRESENTED PAPERS

Comparisons of thyroid hormone withdrawal and rhTSH aided 1850 MBq and 3700 MBq radio iodine (RAI) postsurgical remnant ablation in differentiated thyroid cancer (DTC) Alexander McEwan, Donald Morrish, Chao Ma, Lisa Capelle, Todd McMullen, Naresh Jha and Diane Severin

Epidermal growth factor receptor targeted gold nanoparticles for the enhanced radiation treatment of nonsmall cell lung cancer (poster presentation). Razzak R, Loebenberg R, McEwan A, Guo L, Roa W, Bedard E

Development of a semi-quantitative I-123 mIBG reporting method in high risk neuroblastoma. Poster presentation at the Society of Nuclear Medicine Annual Meeting, Toronto ON, June 15, 2009. Published in J Nucl Med, 2009; 50 (suppl 2):270P. Lewington V, Sever ZB, Giammarile F, Lynch T, McEwan A, Shulkin B, Staudenherz A, Ladenstein R.

Quantitative PET lesion delineation using a three-dimensional adaptive threshold region growing algorithm (RGA): A method for calibration. Poster presentation at the Society of Nuclear Medicine Annual Meeting, Toronto ON, June 15, 2009. Published in J Nucl Med, 2009; 50 (suppl 2):286P.

Gagnon K, Riauka T, McEwan AJB, Robinson D.

Multi-Center Comparison of a PET/CT Calibration Phantom for Imaging Trials. Presentation at the Society of Nuclear Medicine, New Orleans LA, June 16, 2008. Published in J Nucl Med, 2008; 49(Suppl 1): 63P. Kinahan P, Doot R, Christian P, Karp J, Scheuermann J, Zimmerman R, Saffer J, McEwan A

Recommendation for Radioembolization of Hepatic Malignancies Using Yttrium-90 Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). 18th International Congress on Anti-Cancer Treatment, Paris, France, February 6-9, 2007. Published in ICACT Abstract book, February 2007, 239. Nag, S, Kennedy A, Salem R, Murthy R, McEwan A, Nutting C, Benson A, Espat J, Bilbao I, Sharma R, Thomas J, Coldwell D.

A calibration phantom for multi-center PET/CT studies of assessing response to therapy. Oral presentation Society of Nuclear Medicine Annual Meeting, Washington DC, June 2-6, 2007. Published in J Nucl Med, 2007; 48(Suppl 2): 194P-195P. Kinahan PE, Christian PE, Karp JS, Divgi C, Zabal G, Pappas V, and McEwan AJB.

Synthesis, Radiolabeling and Animal Biodistribution of Iozapine, an Analog of Clozapine as a Potential Dopamine D4 Imaging Agent. Poster presentation at the International Symposium for Radioharmaceutical Sciences, Aachen, Germany, May 3, 2007. Published in J Lab Comp Radiopharm, 2007; 50(1):S381. Joshua A, Scott J, Strelkov A, McEwan A, Sharma S, Abrams D, Martin-Iverson M, Silverstone

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Synthesis, Structure Activity Relationship, Radiolabeling and Biodistribution Studies on ERC-9. Presentation at the European Association of Nuclear Medicine Congress, Copenhagen, Denmark, October 15, 2007. Published in *Eur J Nucl Med Mol Imag*; 2007; 34(2):S139. Sharma SK, Joshua AV, Strelkov A, Scott JR, Abrams DN, Postema EJ, McEwan AJB.

[¹⁸F]Fluoroarabinofuranosyl azomycin ([¹⁸F]FAZA): Synthesis, radiofluorination and hypoxia specific PET imaging of murine A431 tumors. International Conference on Application of Radiotracers in Chemical, Environmental and Biological Sciences, Kolkata, India, January 23, 2006. Published in *Application of Radiotracers in Chemical Environmental and Biological Sciences*, Vol 2. Eds: S. Lahiri, D. Nayak, A. Mukhopadhyay, 2006, Saha Institute of Nuclear Physics, Kolkata, India: pp 247-249. Kumar P, Wiebe LI, McEwan AJB, Roselt P, Reischl G, Hicks R, Machulla J.

Diagnostic Yield in PET Imaging of Recurrent Well Differentiated Thyroid Cancer is Dependent on Thyroglobulin Levels. *J Nucl Med* 2006; 47 (Suppl 1): 318P. Papirny MD, Chmielowiec C, Morrish DW, Jha N, McEwan AJB.

A Phase II Study 18-Fluorodeoxyglucose-Defined Tumour Volumes in Patients with Non-Small Cell Lung Cancer Receiving 3D Conformal Radiation Therapy Guided by Breath-Held PET Imaging. Canadian Association of Radiation Oncologists 2006 Annual Scientific Meeting, Calgary, AB, September 13-16, 2006. Published in *Radiotherapy and Oncology* 2006; 80 (Suppl 1): S5. Roa W, Ramcharan J, Alexander A, Pervez N, Tankel K, Scrimger R, Nijjar T, Riauka T, Robinson D, Postema E, McEwan A, Kurien E, Angyalfi S, Smith C.

An Institutional Experience of PET-Guided High-Dose IMRT with Self-Respiratory Gating in the Treatment of Non-Small Cell Lung Cancer. Canadian Association of Radiation Oncologists 2006 Annual Scientific Meeting, Calgary, AB, September 13-16, 2006. Published in *Radiotherapy and Oncology* 2006; 80 (Suppl 1): S31. Lian J, Pervez N, Nijjar T, Quon H, Robinson D, Murray B, Butts C, Joy A, Reiman T, Smylie M, Hanson J, Amanie J, McEwan A, Roa W.

GMP Manufacture and Phase I/II Clinical Studies of [¹⁸F]FAZA, A Marker of Hypoxia, In Cancer Patients at the Cross Cancer Institute. Poster presentation at the Alberta Cancer Board Annual Research Meeting, Banff AB, November 8-10, 2006. Kumar P, Postema E, Wiebe LI, McEwan AJB.

An Alternate Synthesis of 18F-FAZA: A Clinically Used PET Tracer for Tissue Hypoxia. Poster presentation at 16th International Symposium on Radiopharmaceutical Chemistry, Iowa City, Iowa, June 24-28, 2005. Kumar P, Wiebe LI, McEwan AJB.

Radiation Dose Estimates in Patients Receiving Lymphorad™-131 (LR131). Presentation at the Society of Nuclear Medicine 51st Annual Meeting, Philadelphia PA June 19-23, 2004. Abstract in *J Nucl Med* 2004; 45(5): 55P. Stabin MG, Brill AB, Belch A, McEwan A, Riauka T, Stewart D, Kloiber R, Tarantolo S, Hankins J, Soulieres D, Laflamme L, Niesvizky R, Vallabhajosula S, Sung C, Yao Z, Blake L, Gallant G, Klein J.

Low Dose Therapeutic 131I mIBG Therapy in Neuroblastoma Patients Relapsing after Autologous BMT. SIOP XXXVI Congress Meeting, April, 2004. Abstract in *Pediatric Blood & Cancer* 2004; 43(4):377. Desai S, Lewis V, Anderson R, Logus J, Terry C, McEwan AJB.

A Single Institution Study of Low Dose 131I mIBG Therapy for Stage 4 Neuroblastoma—Therapeutic Implications. Poster Presentation at the Advances in Neuroblastoma Research 11th Conference, June 16-19, 2004, Genova, Italy. Abstract in *Programme and Abstracts of the Eleventh Conference on Advances in Neuroblastoma Research*, Genova, 2004, ID308.1:98. Desai SJ, Black K, Amyotte G, Logus JW, Terry C, McEwan AJB.

An Evaluation of the Relationship Among Background Concentration, Tumor Size and Image-Threshold in PET-Based Treatment Planning for Non-Small-Cell Lung Cancer (NSCLC). 2004 Annual Scientific Meeting of the Canadian Association of Radiation Oncologists, Halifax, Nova Scotia. Abstract in *Radiotherapy & Oncology*, 2004, 72(Suppl 1): S1-S2. Yaremko B, Riauka T, Robinson D, Murray B, McEwan A, Roa W.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

The Importance of FDG-PET Scans in Diagnosis and Treatment Response for Locally Recurrent Breast Carcinoma. Poster presentation at 27th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8-11, 2004. Abstract in Proceedings of the 27th Annual San Antonio Breast Cancer Symposium, 2004. Tonkin KS, Chafe S, Severin D, Smylie M, Hanson J, English M, McEwan AJB.

The Efficacy of 201Tl Versus Diagnostic 131I Whole Body Scans in the Follow-Up of Well Differentiated Thyroid Cancer Patients Post-Thyroidectomy. Poster presentation at Society of Nuclear Medicine Annual Meeting, June 23, 2003, New Orleans, LA. Abstract in J Nucl Med 2003; 44 (Suppl 1):335P. Abele JT, Morrish D, Jha N, Amyotte G, McEwan AJB.

Synthesis, Sep-Pak Purification and Radiolysis Studies of Therapeutic Doses of 131IAZA, A Well Known Hypoxia Marker. Poster presentation at 15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, August 10-14, 2003. Abstract in J Label Compd Radiopharm 2003; 46:S1:383. Kumar P, Wiebe LI, McEwan AJB.

Extended Whole-body Clearance of 131I-IAZA in Mice. Poster presentation at 15th International Symposium on Radiopharmaceutical Chemistry, Sydney, Australia, August 10-14, 2003. Abstract in J Label Compd Radiopharm 2003; 46:S1:385. Kumar P, Wiebe LI, McEwan AJB.

Early Clinical Data for LymphoRad™-131 (LR131; Iodine 131 Labelled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. Poster presentation at the American Society for Hematology Annual Meeting, December 6-9, 2003. Abstract in Blood 2003; 102(11): 407a-408a. Belch A, McEwan A, Hewitt J, Stewart D, Kloiber R, Hubbard S, Stabin M, Brill A, Gallant G, Blake L, Klein J.

Assessing Salivary Function in Head and Neck Post XRT Cancer Patients. Poster presentation, European Association of Nuclear Medicine Congress, August 31, - September 4, 2002, Vienna, Austria. Abstract in Eur J Nucl Med 2002; 29 (Suppl 1):S223. Riauka TA, Jackson SA, Jha N, McEwan AJB.

Renogram Analysis Using Multi-Compartmental Modelling with Time Dependent Exchange Coefficients. Poster presentation, European Association of Nuclear Medicine Congress, August 31, - September 4, 2002, Vienna, Austria. Abstract in Eur J Nucl Med 2002; 29 (Suppl 1):S350. Riauka TA, McQuarrie SA, Jackson SA, McEwan AJB.

Preliminary Results of a Phase I/II Dose-Escalation Study Using Neoadjuvant Chemotherapy and Intensity-Modulated Radiotherapy Guided by Combined CT and PET Imaging in Patients with Inoperable Non-Small Cell Lung Cancer. Oral presentation at the CARO 2002 Annual Scientific Meeting, Toronto, October 25-27, 2002. Abstract in Radiother Oncol 2002; 65:S18. Roa W., Butts C, McEwan A, Smylie M, Amanie J, Murray B, Halperin R, Scrimger R, Hilsenteger K, Robinson D.A.

Radioiodinated 123I-ERC-9, N[3-(4-morpholino)-propyl]-n-methyl-2-hydroxy-3-methyl-5-iodobenzylamine: a new potential melanoma imaging agent. Poster presentation at the 5th WHO Conference on Melanoma, Venice, Italy, February 28 - March 3, 2001. Abstract in Melanoma Res 2001; 11(suppl 1): S184. Salopek TG, Scott JR, Joshua AV, Smylie M, Logus JW, Morin CA, McEwan AJB.

Radioiodinated 131I-ERC-9, N[3-(4-morpholino)-propyl]-n-methyl-2-hydroxy-3-methyl-5-iodobenzylamine: Preliminary Report of Phase I Trial of A Potential Melanoma Therapeutic Radiopharmaceutical. Poster presentation at the 5th WHO Conference on Melanoma, Venice, Italy February 28 - March 3, 2001. Abstract in Melanoma Res 2001; 11(suppl 1): S223. Salopek TG, McEwan AJB, Smylie M, Scott JR, Joshua AV, Logus JW, Morin CA.

Radioiodinated 123I-ERC-9, promising new imaging radiopharmaceutical for the detection of melanoma metastasis, appears to be selectively retained by melanoma cells due to its affinity for melanin and interactions with a yet identified cytosolic molecule. Poster presentation at the 5th WHO Conference on Melanoma, Venice, Italy, February 28 - March 3, 2001. Abstract in Melanoma Res 2001; 11(suppl 1): S185. Salopek TG, Jasinska R, Scott JR, McEwan AJB.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Comparative Evaluation of Technetium 99m-MDP Bone Scanning and MRI in the Detection of Spinal Metastases from Primary Breast Cancer. Presented at the Society of Nuclear Medicine Annual Meeting, St. Louis MI, June 4-8, 2000. Abstract in J Nucl Med 2000; 41(5 Suppl); 144P. Davies RG, Halls SB, Chmielowiec CJ, Logus JW, McEwan AJB.

Iodinated ERC9, Promising New Imaging Radiopharmaceutical for the Detection of Melanoma Metastasis, Appears to be Selectively Retained by Melanoma Cells Due to its Affinity for Melanin.

Abstract in J Invest Dermatol 2000; 114(4-542A): 840. Jasinsk R, Salopek T, Chum E, Scott J, McEwan AJB.

I-123 ERC9—A Potential Diagnostic Radiopharmaceutical in Patients with Melanoma. Abstract in J Invest Dermatol 2000; 114(4-543A): 840. Salopek T, Scott J, Smylie M, Morin C, Logus W, McEwan AJB.

Neuroendocrine Tumor Imaging with 123I mIBG versus 111In Octreotide. Presented at the Society of Nuclear Medicine Annual Meeting, St. Louis MI, June 4-8, 2000. Abstract in J Nucl Med 2000; 41(5 Suppl); 310P. Demeter SJ, Morin CA, McEwan AJB.

The Effect of Thyroid Gland Stunning by 131I Sodium Iodide Diagnostic Scans on Subsequent Patient Ablation Doses—A 25 Year Retrospective Study. Poster presentation at the European Association of Nuclear Medicine Annual Congress, Paris, France, September 2-6, 2000. Abstract in Eur J Nucl Med 2000; 27(8): 1154. Chmielowiec C, Logus JW, Morin C, Scott J, Benkovska-Angelova P, McEwan AJB.

A 123I-Epidepride SPECT study of Dopamine in Social Phobia. Poster presentation at the 22nd Annual Meeting of the Canadian College of Neuropsychopharmacology, Halifax, Nova Scotia, June 13, 1999. Li D, Chokka P, Scott J, Logus W, McEwan AJB.

Dopamine and Social Phobia: A SPECT study using Epidepride. Poster presentation at the 54th Annual Society of Biological Psychiatry Meeting, May 15, 1999. Abstract in Biol Psychiatry 1999; 45: S125. Li D, Chokka P, McEwan AJB, Logus W, Scott J, Mantei S, Hanson J, Tibbo P.

Pain Treatment in Bone Metastases - Metastron (Strontium Chloride). Annals of Nucl Med (Taiwan), 1998; 11 (Suppl 1): 3. McEwan AJB.

The Present and Future Role of Radionuclide Unsealed Source Therapy. Presented at the 215th Annual Spring Meeting of the American Chemical Society, Dallas, Texas, March 30, 1998. Abstract in Proceedings of the 215th Annual Spring Meeting of the American Chemical Society, 1998; 13. McEwan AJB, Wiebe LI.

I-123 ERC 9 - A Potential Diagnostic Radiopharmaceutical in Patients with Melanoma. Presented at the Society of Nuclear Medicine Meeting, Toronto, June 7-11, 1998. Abstract in J Nucl Med, 1998; 38(5 Suppl): 10P. McEwan AJB, Scott JR, Smylie MGB, Salopek T, Joshua AV.

Experience with Multiple Dose I-131 mIBG Therapy in Patients with Recurrent Metastatic Neuroblastoma. Presented at the International Society of Pediatric Oncology (SIOP) Meeting, Yokohama, Japan, October 7, 1998. Abstract in Med Ped Oncol, 1998; 31, 4: 232. McEwan AJB, Desai S, Wilson B, Grundy P, Egeler RM, Israels SJ, Yhap MC.

Iodine-123 Iodoazomycin Arabinoside (IAZA) May have a role in Imaging Rheumatoid Arthritis. Poster Presentation at the 44th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas, June 1-5, 1997. Abstract in J Nucl Med, 1997; 38 (5 Supplement): 300-301. McEwan, AJB Skeith KJ, Mannan RH, Davies N, Jamali F, Schmidt, R, Golberg K, Wiebe LI.

Hypoxia Imaging in Patients with Breast Cancer. Poster presentation at the European Association of Nuclear Medicine Congress, Glasgow, Scotland, August 23-27, 1997. Abstract in Eur J Nucl Med, 1997; 24 (8): 1028. McEwan AJB, Catz Z, Morin C, Wiebe LI.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Identification of Hypoxic Regions in Traumatic Brain Injury (TBI). Presented at the European Association of Nuclear Medicine Congress, Glasgow, Scotland, August 23-27, 1997. Abstract in Eur J Nucl Med, 1997; 24 (8): 871. Vinjamuri S, van den Broek M, Maltby P, Stringer RE, Grime JS, Wiebe LI, McEwan AJB, O'Driscoll K, Critchley M.

A Simple Method for Purification and Preparation of I-123 Iodoazamycin Arabinoside (IAZA) for Patient Use. Presented at the European Association of Nuclear Medicine Congress, Glasgow, Scotland, August 23-27, 1997. Abstract in Eur J Nucl Med, 1997; 24 (8): 988. Stringer RE, Wiebe LI, McEwan AJB, Maltby PJ.

High Dose I-131 mIBG Therapy in Patients with Malignant Pheochromocytoma. Poster Presentation at the Society of Nuclear Medicine 43rd Annual Meeting, Denver, Colorado, June 3-6, 1996. Abstract in J Nucl Med 1996; 37: 237P. McEwan AJB, Amyotte G, Morin C, McGowan DG.

High Dose I-131 mIBG Therapy in Patients with Metastatic Carcinoid Tumors. Poster Presentation at the Society of Nuclear Medicine 43rd Annual Meeting, Denver, Colorado, June 3-6, 1996. Abstract in J Nucl Med 1996; 37: 237P. McEwan AJB, Amyotte G, Morin C, McGowan DG, Fields ALA, Smylie M.

Targeted Radiotherapy for Neuroblastoma with High Specific Activity ¹²³I-mIBG. Presented at the 1996 Annual Meeting of the Royal College of Physicians and Surgeons of Canada, September, 1996. Abstract in Clinical and Investigative Medicine 1996; 19s (4): S88. Roa WHY, McEwan AJB, McQuarrie SA, Miller GG, Wu J, Wiebe LI.

Tumor Cell Viability in an In-Vitro Model of Targeted Radiotherapy for Metastatic Human Neuroblastoma. Presented at the 1996 Annual Meeting of the Royal College of Physicians and Surgeons of Canada, September, 1996. Abstract in Clinical and Investigative Medicine 1996; 19 (4): 2. Wu J, Roa WHY, Miller G, McEwan AJB, Krezolek Z.

^{99m}Tc-HL91: A Putative, Non-nitro Containing Agent for Hypoxia-Specific Scintigraphy. Presented at the 43rd Annual Meeting Rad Res Society, San Jose, California, April 1-6, 1995. Abstract Page 183, 1995. Mannan RH, Zhang Z, Wiebe LI, McEwan AJB.

Pharmacokinetics and Radiation Dosimetry of ^{99m}Tc Labelled Monoclonal Antibody 170H.82 in Breast Cancer Patients with No Circulating Antigen. Presented at the International Symposium on Radiopharmacology, Ann Arbor, Michigan, June, 1995. Abstract in The Quarterly Journal of Nuclear Medicine (Ninth International Symposium on Radiopharmacology), 1995; 39: 36-37. McQuarrie SA, McEwan AJB, Noujaim AA, Boniface GR, Golberg K, Golberg L, Sykes TR.

Radiolabelled Tyrosinase Inhibitors for the Detection and Imaging of Neural Crest Tumors and Malignant Melanomas: Radioiodinated 2-iodo-N-acetyl-4-S-cysteaminyl phenol (2-I-N-Ac-4-SCAP). Presented at the International Symposium on Radiopharmacology, Ann Arbor, Michigan, June, 1995. Abstract in The Quarterly Journal of Nuclear Medicine (Ninth International Symposium on Radiopharmacology), 1995; 39: 44-45. Sing S, Chang D, Tandon M, Samra ST, Jimbow K, McEwan AJB, Wiebe LI.

^{99m}Tc-PAO-Azomycin Glucuronide (^{99m}Tc-PAO-AZG): Synthesis and Biological Evaluation as a Marker of Hypoxic Tissues. Presentation at the International Symposium on Radiopharmacology, Ann Arbor, Michigan, June, 1995. Abstract in The Quarterly Journal of Nuclear Medicine (Ninth International Symposium on Radiopharmacology), 1995; 39: 65-66. Kumar P, Mannan R, Zhang Z, McEwan AJB, Wiebe LI.

A Comparison of I-123 mIBG and In-111 Octreotide in Patients with Carcinoid and Pancreatic Neuroendocrine Neoplasms. Presented at the Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis, June, 1995. Abstract in J Nucl Med 1995; 36,5: 126P. McEwan AJB, Akram I, Catz Z, McGowan DG, Morin C, Schmidt R.

Epidipride. Poster presentation at the Society of Nuclear Medicine 42nd Annual Meeting, Minneapolis, June, 1995. Abstract in J Nucl

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Palliative Therapy with Strontium-89 in Patients with Breast Cancer Metastatic to Bone. Presented at the European Association of Nuclear Medicine Congress, Brussels, August, 1995. Abstract in Eur J Nucl Med 1995; 22,8: 808. McEwan AJB, MacLean GD, Starreveld AA, Amyotte G.

3-Dimensional Quantitative Analysis of Regional Cerebral Perfusion Using Tc-99m HMPAO in Normal Volunteers. Presented at the European Association of Nuclear Medicine Congress, Brussels, August, 1995. Abstract in Eur J Nucl Med 1995; 22,8: 842. McEwan AJB, Golberg L, Hanson J, Golberg K, McQuarrie S, McTeer P, Hooper HR.

Whole Body Distribution of I-123 Epidepride, a D2 Receptor Radiopharmaceutical. Poster Presentation at the European Association of Nuclear Medicine Congress, Brussels, August, 1995. Abstract in Eur J Nucl Med 1995; 22,8: 930. McEwan AJB, Tibbo P, Silverstone P, Joshua A, Golberg K, Scott J.

Treatment of Carcinoid with I-131 meta-Iodobenzylguanidine - A Follow-up Study. Presented at the European Association of Nuclear Medicine Congress, Brussels, August, 1995. Abstract in Eur J Nucl Med 1995; 22,8: 941. Morin C, McEwan AJB, Akram I, Catz Z.

^{99m}Tc-1-(N-Diphenylphosphinoacetyl)glycylglycyl-2-aminoethyl)-2-nitroimidazol: a New Agent for Non-Invasive Imaging of Tissue Hypoxia. Presented at the 11th International Symposium on Radiopharmaceutical Chemistry, Vancouver, BC. Abstract in J Labelled Comp Radiopharm, 1995; 37: 205-207. Zhang Z, Mannan RH, McEwan AJB, Wiebe LI.

High Yield Radioiodination of Sugar Analogs by Exchange Labelling. 11th International Symposium on Radiopharmaceutical Chemistry, Vancouver, BC. Abstract in J Labelled Comp Radiopharm, 1995; 37: 179. Lee HC, Kumar P, McEwan AJB, Mercer JR.

Striatal Dopamine D2 Receptor Binding with ¹²³I-Epidepride: An In Vivo SPECT Study. Presentation at the 4th International Symposium, Imaging of the Brain in Psychiatry and Related Fields, ISNIP '95, Frankfurt, Germany, November 1-5, 1995. Abstract in Psychiatry Research, 1997; 68: 180. Tibbo P, Silverstone PH, McEwan AJB, Scott J, Joshua A, Golberg K.

Iodine-131, Thallium-201 and Technetium-99m MIBI Imaging for Residual, Recurrent and Metastatic Disease in Follow-up of Thyroid Cancer Patients. Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. Abstract published in Clin Nuc Med, 1994; 19, 10: 932. A.J.B. McEwan, Imad Akram, M.E. Hoskinson .

Treatment of Patients with Metastatic Carcinoid Tumor with ¹³¹I Meta Iodobenzylguanidine (mIBG). Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994 Abstract published in Clin Nuc Med, 1994; 19, 10: 933. A.J.B. McEwan, I. Akram, R. Schmidt, R. Hooper, Z. Catz.

Radioimmunoscinigraphy with MAb 174H.64 in Head & Neck Cancer Patients: First Clinical Results. Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. Abstract published in Clin Nuc Med, 1994; 19, 10: 932. A.J.B. McEwan, G.D. MacLean, L. Golberg, G.R. Boniface, S. McQuarrie, I. Akram, K. Golberg, G. Amyotte, A.A. Noujaim.

Preliminary Results of a Phase II Clinical Trial Utilising Tru-Scint®AD™ in Primary and Metastatic Breast Cancer. Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. Abstract published in Clin Nuc Med, 1994; 19, 10: 932. A.J.B. McEwan, G.D. MacLean, L. Golberg, K. Golberg, G.R. Boniface, T. Sykes, S. McQuarrie, G. Amyotte, A. Noujaim.

An Evaluation of ¹²³I-Iodoazomycinarabioside (IAZA) as a Marker of Tissue Hypoxia in Patients with Diabetes Mellitus. Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. Abstract published in Clin Nuc Med, 1994; 19, 10: 932. A. Al Arafaj, E.A. Ryan, K. Hutchison, J. Mercer, L.I. Weibe, A.J.B. McEwan.

Modelling and Dosimetry of Monoclonal Antibody 170H.82 in Breast Cancer. Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. Abstract published in Clin Nuc Med, 1994; 19, 10: 932. McQuarrie SA, McEwan AJB, Golberg L, Golberg K, Boniface GR, Noujaim AA.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

The Professor: An Interactive Digital Teaching File for Nuclear Medicine and Radiology. Presented at the Society of Nuclear Medicine 41st Annual Meeting, Orlando, Florida, June, 1994. Abstract in J Nucl Med 1994; 35,5: 272P. Scott DV, Mah E, Filipow L, Maguire C, Warshawski R, McEwan AJB.

Evaluating Radioimmunosciintigraphy in Patients with Breast Cancer. Presented at the European Association of Nuclear Medicine Congress, Dusseldorf, Germany, August, 1994. Abstract in Eur J Nucl Med 1994; 21,8: 748. McEwan AJB, MacLean G, Golberg L, Akram I, Boniface G, McQuarrie S, Golberg K, Sykes T, Amyotte G, Noujaim A.

Modelling and Dosimetry of Monoclonal Antibody 170H.82 (Tru-Scint®AD™) in Breast Cancer. Poster presentation at the European Association of Nuclear Medicine Congress, Dusseldorf, Germany, August, 1994. Abstract in Eur J Nucl Med 1994; 21,8: 874. McQuarrie SA, McEwan AJB, Golberg L, Golberg K, Boniface GR, Noujaim AA.

Development of a New Technetium Complex for Hypoxia Imaging: A Technetium(V) Amine Nitrophenol Complex. Presented at the Fourth International Symposium on Technetium in Chemistry and Nuclear Medicine, Padova, Italy, September, 1994. Zhang Z, Mannan RH, Wiebe LI, McEwan AJB.

Strontium-89 to Treat Patients with Breast Cancer Metastatic to Bone. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S44. McEwan AJB, Amyotte G, MacLean GD, Nabholtz, J-M, Lees AW, Krause B, Starreveld AA.

I-123-Iodoazomycinarabinoside (IAZA) in Patients with Diabetes Mellitus and Peripheral Vascular Disease. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S23. McEwan AJB, Al Arafaj A, Ryan EA, Hutchison K, Mercer J, Weibe LI, Mannan R.

Tc-99m MAb 170H.82 in the Evaluation of Locoregional Disease in Patients with Breast Cancer. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S15. McEwan AJB, Akram I, Boniface G, Golberg L, McQuarrie SA, Golberg K, Amyotte G, Hornig B, Noujaim AA, MacLean GD.

Thyroid Cancer Follow-Up Comparing Iodine-131, Thallium-201 and Technetium-99m MIBI. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S25. Akram I, Hoskinson M, McEwan AJB, Catz Z.

Radioimmunosciintigraphy with MAb-174H.65 (Tru-Scint®SQ™) in Patients with Head and Neck Cancer. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S15. Akram I, Jha N, MacLean GD, Boniface G, Golberg L, McQuarrie SA, Golberg K, Amyotte G, Hornig B, Noujaim AA, McEwan AJB.

Effects of Antineoplastic Drugs Associated with In Vitro Labeling of Erythrocytes in Multigated Cardiac Studies. Presented at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S70. Schmidt RP, Morin C, McEwan AJB.

Pharmacokinetics and Radiation Dosimetry of MAb Tru-Scint®AD™ in Breast Cancer Patients. Poster presentation at the 6th World Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, October, 1994. Abstract in Eur J Nucl Med 1994; 21,10 (Suppl): S129. McQuarrie SA, McEwan AJB, Golberg K, Golberg L, Boniface G, Noujaim AA.

Tc-99m 170H.82 (Tru-Scint®AD™): A Monoclonal Antibody for the Evaluation of Patients with Breast Cancer--A Preliminary Analysis. Current Status and Future Directions of Immunoconjugates V Conference, Fort Lauderdale, FL, January, 1993. Abstract in Diagn Oncol 1993; 3:32.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

A Pharmacokinetic Comparison of Murine and Chimeric Forms of the 99mTc Labelled 174H.64 Monoclonal Antibody. Presented at the Eighth International Symposium on Radiopharmacology, Ghent, Belgium, September, 1993. Abstract in J Nucl Biol Med 1993; 37(3): 158

McQuarrie SA, Baum RP, Golberg L, Niesen A, Golberg K, Noujaim AA, McEwan AJB.

Radiolabelled, Sugar-Coupled 2-Nitroimidazoles as Markers of Hypoxic Tissue. Presented at the Eighth International Symposium on Radiopharmacology, Ghent, Belgium, September, 1993. Abstract in J Nuc Biol Med 1993; 37(3): 158. Mercer JR, McEwan AJB, Wiebe LI, Parliament M, Urtasun R, Mannan RH, Ryan E, Humen D.

An Analysis of the Cost Effectiveness of Adjunct Strontium-89 in Patients with Carcinoma of the Prostate. Presented at the European Association of Nuclear Medicine Congress, Lausanne, Switzerland, October, 1993. Abstract in E J Nucl Med 1993; 34: 987. McEwan AJB, Porter A, McGowan D, Amyotte G, MacGillivray J, Berringer J, Member of the Trans Canada Collaborative Group

Does gallium uptake in the pulmonary hila predict involvement by non-Hodgkins lymphoma? Presented at the British Nuclear Medicine Society Annual Meeting, London, UK, April, 1992. Abstract in Nuc Med Commun 1992; 13,4:219. McEwan AJB, Champion P, Groshar D, Palmer M, Catz Z, Belch A.

I-123 IAZA: a novel radiopharmaceutical for imaging hypoxic tissue; preliminary results of a pilot study. Presented at the British Nuclear Medicine Society Annual Meeting, London, UK, April, 1992. Abstract in Nuc Med Commun 1992; 13,4:220. McEwan AJB, Urtasun R, Parliament M, Mercer J, Mannan R, Chapman J, Golberg L, Wiebe L.

Adjuvant Strontium-89 in prostate cancer: First report of the Trans-Canada Collaborative Study. Presented at the British Nuclear Medicine Society Annual Meeting, London, UK, April, 1992. Abstract in Nuc Med Commun 1992; 13,4:212. McEwan AJB, Porter A, McGowan D, Amyotte G, Members of the Trans-Canada Collaborative Group.

Phase I trial evaluating I-131 mIBG therapy in patients with metastatic carcinoid and pheochromocytoma. Presented at the British Nuclear Medicine Society Annual Meeting, London, UK, April, 1992. Abstract in Nuc Med Commun 1992; 13,4:213. McEwan AJB, Fields A, Jensen J, McGowan D.

Tc-99m 170H.82: A Monoclonal Antibody for the Evaluation of Patients with Breast Cancer. Presented at the European Association of Nuclear Medicine Congress, Lisbon, Portugal, August, 1992. Abstract in Eur J Nuc Med 1992; 19,8:576. McEwan AJB, MacLean G, Golberg L, Groshar D, Boniface G, Sykes T, Noujaim A.

Adjuvant Strontium-89 in Prostate Cancer: First Report of the Trans-Canada Collaborative Study. Presented at the European Association of Nuclear Medicine Congress, Lisbon, Portugal, August, 1992. Abstract in Eur J Nuc Med 1992; 19,8:608. McEwan AJB, Porter A, McGowan D, Amyotte G.

A New In Vivo Marker of Tumor Hypoxia; Preliminary Clinical Results. Presented at the European Association of Nuclear Medicine Congress, Lisbon, Portugal, August, 1992. Abstract in Eur J Nuc Med 1992; 19,8:579. McEwan A, Urtasun R, Parliament M, Mercer J, Mannan R, Chapman J, Golberg L, Wiebe L.

Cerebral Etiology of Urinary Urge Incontinence in the Elderly. Royal College of Physicians and Surgeons of Canada Annual Meeting, September, 1992. Abstract in Clinical and Investigative Medicine 1992; Suppl 15,4:A52. McCracken PN, Griffiths DJ, Harrison GM, Gormley EA, Moore K, Hooper R, McEwan AJB, Triscott J.

Non-Invasive Detection of Chronic Hypoxia with 123I-Iodoazomycin Arabinoside (IAZA): Correlation with Tumor Perfusion and Possible Implications for Radiotherapy. Royal College of Physicians and Surgeons of Canada Annual Meeting, September, 1992. Abstract in Clinical and Investigative Medicine 1992; Suppl 15,4:A138. Parliament M, Groshar D, Urtasun R, McEwan AJB, Mannan R,

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Interim analysis of a multi centre trial of Strontium-89 as adjuvant therapy. British Nuclear Medicine Society Annual Meeting, London, UK, April, 1991. Nuc Med Commun 1991; 12(4); 255. McEwan AJB, Reid R, Porter AT, and members of the Canadian Strontium User Group.

Patterns of HMPAO distribution after radiotherapy. British Nuclear Medicine Society Annual Meeting, London, UK, April, 1991. Nuc Med Commun 1991; 12(4); 281. McEwan AJB, Hooper HR, Urtasun R, Huyser-Wierenga D.

Thallium-201 imaging: A sensitive and specific method for the follow-up of differentiated thyroid carcinoma. Presented at Society of Nuclear Medicine, 38th Annual Meeting, Cincinnati, Ohio, June, 1991. Abstract in J Nucl Med 1991; 32,5: 921. McEwan AJB, Tracey KP, Catz Z, Glazebrook GA, Morrish DW.

Strontium-89 as an adjuvant to local external beam radiotherapy; Preliminary results of the trans-Canada multi centre study. Presented at Society of Nuclear Medicine, 38th Annual Meeting, Cincinnati, Ohio, June, 1991. Abstract in J Nucl Med 1991; 32,5: 918. Reid R, McEwan AJB, Porter AT, and members of the Canadian Strontium User Group.

Tc labelled 170H.82 monoclonal antibody in radioimmunoguided colorectal surgery...A case study. Eur J Nuc Med, 1990; 16 Suppl: S54. Golberg L, McEwan AJB, Brzezinski W, Wiens E, Noujaim AA, Longenecker BM, Sykes T, MacLean GD.

SPECT imaging of Tc-99m 170H.82 monoclonal antibody in patients with primary and metastatic adenocarcinoma. Eur J Nuc Med, 1990; 16 Suppl: S68. Golberg L, McEwan AJB, Noujaim AA, Longenecker BM, Sykes T, MacLean GD.

Evaluation of In-111 and Tc-99m labelled monoclonal antibody for pre-operating imaging in primary colorectal cancer. Eur J Nuc Med, 1990; 16 Suppl: S54. Golberg L, McEwan AJB, Brzezinski W, Wiens E, Noujaim AA, Longenecker BM, Sykes T, MacLean GD.

Characterization of Collimators for a Surgical Probe Detection System. Eur J Nuc Med, 1990; 16 Suppl: S81. Logus JW, Golberg L, McEwan AJB.

A Three Dimensional Programme to Quantitatively Analyse Cerebral Perfusion from HMPAO Images: Normal and Pathophysiological Data. British Nuclear Medicine Society Meeting, London, England, April, 1990. Nucl Med Commun 1990; 11(3); 221. McEwan AJB, Hooper HR, Kotchon T, McTeer P, Hooper PM.

Initial Clinical Experience with Tc-99m 170H.82, a Novel Panadenocarcinoma Monoclonal Antibody. British Nuclear Medicine Society Meeting, London, England, April, 1990. Nucl Med Commun 1990; 11(3); 206. McEwan AJB, MacLean GD, Longenecker BM, Golberg L, Sykes TR, Noujaim AA.

Geriatric urge incontinence: basic dysfunction and contributory factors. International Continence Society Meeting, Aarhus, Denmark, September, 1990, Abstract in Neurourol Urodynam 1990; 9:406-407. Griffiths DJ, McCracken PN, Harrison GM, McEwan AJB.

Comparison of thallium-201 (Tl-201) and I-131 scintigraphy in the follow-up of patients with thyroid carcinoma. Annual Meeting, Prairie Provinces Chapter, Society of Nuclear Medicine, Edmonton, Alberta, April 6-8, 1989. J Nucl Med 1989; 30: 914 (abstract). Tracey KP, Catz Z, Glazebrook GA, Morrish DW, Secter B, McEwan AJB.

Quantification of hexamethylpropyleneamine oxime (HMPAO) distribution in pediatric psychiatric patients. Annual Meeting, Society of Nuclear Medicine, St. Louis, June 13-16, 1989. J Nucl Med 1989; 30: 812 (abstract) McEwan AJB, Blackman M, Paterson W, Hooper HR.

Treatment of patients with metastatic carcinoid tumor with 131-I meta iodobenzylguanidine (mIBG). Annual Meeting, Society of Nuclear Medicine, St. Louis, June 13-16, 1989. J Nucl Med 1989; 30: 826 (abstract) McEwan AJB, Schmidt BB, Catz Z, Hooper HR.

**ABSTRACTS AND PRESENTED PAPERS - CONTINUED**

Clearance of I-123 meta iodobenzylguanidine (mIBG) in patients with autonomic neuropathy. Nucl Med Commun 1988; 9(3): 197. McEwan AJB, Ryan EA, Kappagoda CT, Muldowney SM, Seethram K.

Uptake of Tc-99m Hexamethylene-propyleanamine oxime (HM-PAO) by metastatic renal cell carcinoma. Nucl Med Commun 1988; 9(3): 212. McEwan AJB, Catz Z, Schmidt RP, Porter AT, Hooper HR.

Treatment with Strontium-89 (Sr-89) in patients with prostate cancer following wide field irradiation. Nucl Med Commun 1988; 9(3): 179. McEwan AJB, Porter AT, Venner PM, Amyotte GA.

Strontium-89: Treatment results & kinetics in patients with painful metastatic prostate & breast cancer in bone. J Nucl Med 1988; 29(5) Suppl; 763. Robinson RG, Blake GM, Preston DF, McEwan AJB, Spicer JA, Martin NL, Wegst AV, Ackery DM.

Tc-99m Hexamethyl-propyleneamine oxime (HM-PAO) uptake in primary and metastatic brain tumors. J Nucl Med 1988; 29(5) Suppl; 895. Tanton E, Catz Z, Hooper HR, Schmidt RP, McEwan AJB.

Strontium-89 (Sr-89) to palliate patients with metastatic prostate cancer following wide field radiotherapy. J Nucl Med 1988; 29(5) Suppl; 775. McEwan AJB, Porter AT, Venner PM, Amyotte GA.

The use of Strontium 89 in the palliation of patients with metastatic prostate cancer following wide field radiotherapy. Annual Meeting, European Society for Therapeutic Radiology and Oncology, Den Haag, September, 1988. Porter AT, McEwan AJB, Venner PM, Amyotte GA.

Monoclonal antibodies and synthetic carbohydrate antigens: A unique approach to cancer immunoscintigraphy. BNMS Annual Meeting, London, April 13-15, 1987.

McEwan AJB, MacLean GD, Catz Z, Selvaraj S, Suresh MR, Sykes TR, Abdi E, Noujaim AA, Longenecker BM.

An evaluation of mIBG uptake by metastatic carcinoid tumor. BNMS Annual Meeting, April 13-15, 1987.

Lewington V, McEwan AJB, Fine D, Catz Z., Fields ALA, Harbora D, Ackery DM.

Cancer immunoscintigraphy utilizing monoclonal antibodies raised against synthetic carbohydrate antigens: A novel approach. 34th Annual Meeting for Society of Nuclear Medicine, June 2-4, 1987.

McEwan AJB, MacLean GD, Catz Z, Selvaraj S, Suresh MR, Sykes TR, Abdi E, Noujaim AA, Longenecker BM.

I-131 meta iodobenzylguanidine (mIBG) in the diagnosis and treatment of carcinoid syndrome. Annual Meeting, Society of Nuclear Medicine, Toronto, June, 1987. McEwan AJB, Catz Z, Fields ALA, Lewington V, Harbora D, Fine D, Ackery DM.

Static and functional imaging in the management of steroid induced osteonecrosis after renal transplantation. Proc World Congr Nucl Med Biol, 1985. McEwan AJB, Macleod MA, Slapak M.

Therapy of malignant pheochromocytoma with 131I-meta iodobenzyl-guanidine. Eur J Nuc Med 1985; 11(2/3): A17. McEwan AJB, Blake G, Hall, VC, Ackery DM.

Pheochromocytoma imaging using 131I-meta iodobenzylguanidine. Proc Br Nucl Med Soc Annual Meeting, 1984. McEwan AJB, Tippett PA, Condon BR, Wyeth P, Ackery DM.

Clinifeed 400: a standardized test meal to study gastric emptying in normal subjects and the effect of LM24056. Proc World Congr Gastroenterol, Stockholm, June 13-19, 1982. McEwan AJB, Milton-Thompson GJ, Macleod MA, Hunt RH.

An interpretation of skeletal functional imaging. Proc World Congr Med Phys Biomed Eng, Hamburg, 1982. Houston AS, McEwan AJB, Macleod MA.



SCIENTIFIC EXHIBITS

Technetium-99m (Tc-99m) pertechnetate (TcO₄) imaging with cyclotron produced Tc-99m compared with generator Tc-99m. A. McEwan, S. McQuarrie, D. Abrams, K. Gagnon, J. Wilson, E.E. Turcotte, B. Guerin, R. Lecomte. Presentation at the SNM June 8 – 13, 2012

Factors favouring early nodal recurrence in papillary thyroid carcinoma (PTC) A. McEwan, L. Capelle, T. McMullen, D. Morrish. Presentation at the SNM June 8 – 13, 2012

18F-FDG-PET scans and high dose of iodine-131 (I-131) treatment in patients with elevated thyroglobulin and negative iodine-131 scan differentiated thyroid carcinoma. A. McEwan, C. Ma, D. Morrish, T. McMullen, L. Capelle, D. Severin, N. Jha. Presentation at the SNM June 8 – 13, 2012

Cyclotron production of 99mTc: Recycling of enriched 100Mo metal targets. K.Gagnon, J.S.Wilson, C.M.B.Holt, D.N.Abrams, A.J.B.McEwan, D.Mitlin, S.A.McQuarrie. Presentation at the EANM 2011

The Design, Development and Clinical Application of Radiopharmaceuticals for Diagnostic Imaging of Radioresistant Hypoxia in Solid Tumors at the Cross Cancer Institute. AJB McEwan, E Postema, R Urtasun, M Parliament, P Kumar, LI Wiebe. Presentation at the Care about Cancer Conference in Edmonton, Alberta, June 17, 2011.

The potential of using discordance of estrogen PET (FES-PET) and glucose PET (FDG-PET) scans and pathologic characteristics including HER2 to predict for hormone insensitivity in women with metastatic breast cancer. Poster presentation at the Breast Cancer Symposium in San Antonio, CA. Tonkin K, Bramwell V, Vandenberg T, Pritchard K, Shepherd L, Ghosh S, McEwan A

The advantages of using discordance of estrogen PET (FES-PET) and glucose PET (FDG-PET) scans along with Ki67 and HER2 to predict for hormone insensitivity in women with metastatic breast cancer. Tonkin KS, Joy A, Basi S, Fenton D, Armanie J, Mackey J, Tankel K, Descenes J, McEwan A.

Practical Issues in Establishing PET Scanning in Your Centre (Based on the Edmonton PET Centre Experience). Poster presentation at Oncology Nursing, Moncton NB, October 2-5, 2005. English M, McEwan AJB, McQuarrie S.

Characterization of Facilitated Glucose Transporters in Porcine Neonatal Islets. Poster presentation at Canadian Diabetes Association Meeting, Edmonton, AB, October 19, 2005. Manolescu A, Harb G, Mercer J, McEwan A, Korbutt GS, Cheeseman CI.

PET Radiopharmaceuticals at the Cross Cancer Institute PET Centre: [18F]FAZA, a Marker of Tissue Hypoxia. Poster presentation at the Alberta Cancer Board Research Conference, Banff, Alberta, November 8-10, 2005. Kumar P, Hicks R, Machulla H-J, Piert M, Rischin D, Reischl G, Roselt P, McEwan AJB, Wiebe LI.

PET Radiopharmaceuticals at the Cross Cancer Institute PET Centre: [18F]FLT for In Vivo Cell Proliferation Imaging. Poster presentation at the Alberta Cancer Board Research Conference, Banff, Alberta, November 8-10, 2005. Sun WY, Wilson J, Zhou A, Doerksen C, Knaus EE, Kumar P, McEwan AJB, Wiebe LI.

Automated Production of [18F]-16- α -Fluoroestradiol (18F-FES) at Edmonton PET Centre: Improved Purification, Stability Studies and PET Imaging in ER Positive Breast Cancer Patients. Poster presentation at the Alberta Cancer Board Research Conference, Banff, Alberta, November 8-10, 2005.

Kumar P, Mercer J, Doerksen C, Tonkin K, McEwan AJB.

Regulatory Issues of Positron Emission Tomography (PET) Imaging As Experienced at the Cross Cancer Institute (CCI), Edmonton. Poster presentation at the Alberta Cancer Board Research Conference, Banff, Alberta, November 8-10, 2005. Landon M, McEwan AJB,

**SCIENTIFIC EXHIBITS - CONTINUED**

Preliminary results of Internal Mammary MRI—follow-up of suspected positive cases. Poster Presentation at Alberta Cancer Board Annual Scientific meeting, Nov 12-14, 2003, Banff, Alberta. Halls SB, Narnaware A, Jeske D, Kvamme K, Piva I, Mackey JR, Chmielowiec C, McEwan AJB.

Virtual Dissection MRI of Internal Mammary Lymph Nodes. Poster presentation at Alberta Cancer Board Annual Scientific Meeting, Banff, Alberta, November 10-11, 2002. Halls SB, McEwan AJB, Chmielowiec C, Mackey J, Narnaware

18FAZA, a putative PET marker of tissue hypoxia: Preliminary in vitro and in vivo data. Poster presentation at XIII Congreso Argentino de Biología y Medicina Nuclear, Buenos Aires, Argentina, November 2-4, 2001. Piert M, Patt M, Machulla H-J, Kumar P, Link T, Schwaiger M, McEwan AJB, Wiebe LI.

Phase II Study of Iodine-123 Radioiodinated N [3-(4-Morpholino)-Propyl]-N-Methyl-2-Hydroxy-3-Methyl-5-Iodobenzylamine (ERC9) in Evaluating Patients with Melanoma. Presented at the Canadian Society of Nuclear Medicine Annual Meeting, Mont Tremblant, Quebec, April 1-4, 2000.

McEwan AJB, Scott JR, Joshua AV, Smylie MG, Logus JW, Salopek TG.

131I mIBG Therapy in Pheochromocytoma: Experience with a Multiple Dose Regimen. Presented at the Canadian Society of Nuclear Medicine Annual Meeting, Mont Tremblant, Quebec, April 1-4, 2000.

McEwan AJB, Chmielowiec CJ, Morin CA, McGowan DG.

Phase I Study of 111In Octreotide Therapy in Patients with Neuroendocrine Tumors. Presented at the Canadian Society of Nuclear Medicine Annual Meeting, Mont Tremblant, Quebec, April 1-4, 2000.

McEwan AJB, Schmidt RP, Morin CA, Logus JW, Chmielowiec CJ.

The Relationship of Striatal Dopamine to Social Phobia and Gender: A 123I-Epidopride SPECT Study. Poster presentation at the 153rd Annual Meeting of the American Psychiatric Association, Research Colloquium for Junior Investigators, May 14, 2000. Li DM, Chokka P, McEwan AJB, Logus W, Mantei S, Hanson J, Tibbo P.

A SPECT Study of Gender and Striatal Dopamine. Poster Presentation at the 55th Annual Meeting of the Society of Biological Psychiatry, May 12, 2000. Li DM, Chokka P, McEwan AJB, Logus W, Mantei S, Hanson J, Tibbo P.

Uptake of [125I]-5-Iodo-2'-Fluoro-2'-Deoxyuridine ([125I]-FIRU) in Murine Tumors Following In Vivo Gene Transfer with Adenoviral Vectors. Poster presentation at the 9th European Symposium of Radiopharmacy & Radiopharmaceuticals, Lillehammer, Norway, March 6-9, 1999. Morin KW, Duan W, McEwan AJB, Knaus EE, Wiebe LI.

Monitoring Adenovirus-Mediated Gene Transfer Using Radiolabelled FIRU and HSV-1 Thymidine Kinase as a Reporter. Poster presentation at the 1999 Canadian Society of Nuclear Medicine Annual Scientific Meeting, Banff, Alberta. March 27-31, 1999. Morin KW, Duan W, McEwan AJB, Knaus EE, Wiebe LI.

Renogram Analysis Using Multi-Compartmental Modeling and Simulated Annealing. Presentation at the 1999 Canadian Society of Nuclear Medicine Annual Scientific Meeting, Banff, Alberta. March 27-31, 1999. Riauka TA, Jackson SA, McQuarrie SA, Guijon J-C, McEwan AJB.

Clinical 123I-IAZA: Hypoxia Imaging and Radiodosimetry. Poster presentation at the 3rd Peter MacCallum Cancer Symposium, Melbourne, Australia, November 7-10, 1999. Wiebe LI, Stypinski D, McEwan AJB.

A Protocol for the Preparation of Clinical Doses of Radioiodinated IAZP for Imaging Tumour Hypoxia. Presented at the Alberta Cancer Board Research Retreat, Calgary, Alberta, November 9-10, 1998. Kumar P, Asikoglu M, McEwan AJB, Schmidt RP, Wiebe LI.



SCIENTIFIC EXHIBITS - CONTINUED

Therapy of Neuroendocrine Tumors with Indium-111 Octreotide: A Report of Multiple Treatments in Two Patients. Presented at the CANM/SNMC Conjoint National Scientific Meeting, Ottawa, November 9-12, 1997. McEwan AJB, Schmidt R, Morin C.

Hypoxia Imaging in Patients with Breast Cancer. Presented at the CANM/SNMC Conjoint National Scientific Meeting, Ottawa, November 9-12, 1997. McEwan AJB, Catz Z, Morin C, Wiebe LI.

Multi-Dose Strontium-89: A Phase 1 Protocol. Presented at the CANM/SNMC Conjoint National Scientific Meeting, Ottawa, November 9-12, 1997. McEwan AJB, McGowan DG, Amyotte G.

^{99m}Tc-MAb-170 in the Detection of Gynaecological Malignancies. Presented at the Thirteenth International Hammersmith Conference in Chania, Greece, May 27-30, 1996. Boniface G, Pankovich J, Alexander C, Villena-Heinsen CE, Cohen P, McEwan AJB.

Radiopharmaceutical Palliation of Pain in Cancer Metastatic to Bone. Presented at the 6th Asia and Oceania Congress of Nuclear Medicine and Biology, October, 1996. McEwan AJB.

High Dose I-131 mIBG Therapy in Patients with Malignant Pheochromocytoma. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. Morin C, McEwan AJB, Catz Z, McGowan DG.

I-131 mIBG Therapy in Patients with Metastatic Carcinoid Tumors. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. Morin C, McEwan AJB, McGowan DG, Fields ALA, Catz Z, Smylie M.

A Comparison of I-123 mIBG and In-111 Octreotide in Patients with Neuroendocrine Neoplasms. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. Morin C, McEwan AJB, Catz Z.

The Role of Multi-Gated Cardiac Blood Pool Scintigraphy (MUGA) for Monitoring Chemotherapy Induced Cardiotoxicity in Cancer Patients. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. McEwan AJB, Morin C, Catz Z.

Hypoxia-Targetted ¹²³I-Iodoazomycin Arabinoside Imaging of the Adjuvant Arthritis Rat Model. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. McEwan AJB, Skeith KJ, Mannan RH, Davies N, Jamali F, Wiebe LI.

¹³¹I mIBG Therapy - A Critical Review of the Literature. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. McEwan AJB, Golberg L.

¹²³I-Iodoazomycin Arabinoside -- a Possible Marker of Hypoxia in Rheumatoid Arthritis. Presented at the Canadian Association of Nuclear Medicine Annual Scientific Meeting, Quebec City, Quebec, October, 1996. McEwan AJB, Skeith KJ, Mannan RH, Davies N, Jamali F, Wiebe LI

Hypoxic Tissue Imaging with Radioiodinated Nitroimidazoles: The Development and Clinical Experience with ¹²³I-Iodoazomycin Arabinoside (¹²³I-IAZA). Presented at 6th European Symposium on Radiopharmacy and Radiopharmaceuticals, Graz, Austria, March 5-8, 1995. Mercer JR, Al-Arafaj A, Hutchison K, Kumar P, Mannan RH, McEwan AJB, Parliament MJ, Ryan EA, Urtasun R, Wiebe LI.

Use of Strontium-89 in Patients with Breast Cancer Metastatic to Bone. Presented at Oncology Nursing Society Meeting, Anaheim, Florida, April, 1995. Amyotte G, McEwan AJB.

Striatal Dopamine D2 Receptor Binding with ¹²³I-Epidopride: An In Vivo SPECT Study. Presentation at the 18th Annual Meeting of the

**SCIENTIFIC EXHIBITS - CONTINUED**

A Comparison of I-123 mIBG and In-111 Octreotide in Patients with Carcinoid and Pancreatic Neuroendocrine Neoplasms. Presented at the Alberta Cancer Board Annual Research Meeting, Edmonton, Alberta, November, 1995. McEwan AJB, Akram I, Catz Z, McGowan DG, Morin C, Schmidt R.

^{99m}Tc-1-(N-Mercaptoacetyl-glycyl-glycyl-2-aminoethyl)-2-nitroimidazol: Synthesis and Biological Evaluation as a Marker of Tissue Hypoxia. Presented at the 1995 International Chemical Congress of Pacific Basin Societies, Honolulu, Hawaii, December, 1995. Zhang Z, Mannan RH, McEwan AJB, Wiebe LI.

MAB 174H.64 Scintigraphy in Head & Neck Cancer Patients: Preliminary Results. Presented at the VI Diagnostic and Therapeutic Applications of Radiolabeled Antibodies and Receptors for Diagnostic and Therapeutic Purposes, Key Biscayne, Florida, January, 1994. McEwan AJB, MacLean GD, McQuarrie S, Parliament MB, Jha N, Golberg L, Golberg K, Amyotte G, Noujaim AA.

Classification of Alzheimer's and Normal HMPAO SPECT Images Using a Neural Network. Society of Nuclear Medicine Mid-Winter Meeting, Seattle, Washington, February, 1994. Dawson M, Dobbs A, Hooper R, Jackson SA, Duncan M, Triscott J, McEwan AJB.

A Cost Analysis of Adjunct Strontium-89 (Metastron). Presented at the Nuclear Medicine Canada '94 Meeting, Banff, Alberta, March 1994. A. McEwan, D. McGowan, G. Amyotte, J. MacGillivray, J. Berringer.

Preliminary Analysis of Tc-99m 170H.82 (Tru-Scint AD) in the Evaluation of Patients with Primary or Metastatic Breast Carcinoma. Presented at the 9th Annual International Research Group on Immunoscintigraphy and Immunotherapy Meeting, Velden, Austria, April, 1994. McEwan AJB, Boniface G, MacLean G, Golberg L, Golberg K, Sykes T, McQuarrie S, Amyotte G, Noujaim AA.

A Cost Analysis of Strontium-89 (Metastron). Presented at the XI European Association of Urology Congress, Berlin, Germany. McEwan AJB, McGowan D, Amyotte G, MacGillivray J, Berringer J.

A Comparison of Murine Vs. Chimeric MAb-174 for the Detection of Squamous Cell Carcinoma of the Head and Neck. Eighth Annual International Research Group in Immunoscintigraphy and Immunotherapy, Lake Maggiore, Italy, March, 1993. Baum R, Niesen A, McEwan AJB, MacLean GD, Golberg L, Boniface G, McQuarrie S, Noujaim A, Hör G.

Tc-99m 170H.82 (Tru-Scint®AD™): A New Monoclonal Antibody for Imaging Breast Cancer--A Preliminary Analysis. Poster at the Society of Nuclear Medicine Annual Meeting, Toronto, Ontario, June, 1993.

An Analysis of the Cost Effectiveness of Adjunct Strontium-89 in Patients with Carcinoma of the Prostate. Poster at the European Association of Nuclear Medicine Congress, Lausanne, Switzerland, October, 1993.

A Cost Analysis of Adjunct Strontium-89 (Metastron). Poster at the XIth European Association of Urology Congress, Berlin, Germany, July, 1993.

An Analysis of the Cost Effectiveness of Strontium-89 with Carcinoma of the Prostate. British Nuclear Medicine Society Annual Meeting, London, England, April, 1993. McEwan AJB, Porter A, McGowan D, Amyotte G, MacGillivray J, Berringer J.

Strontium-89 in Patients with Carcinoma of the Prostate: Analysis of Cost Effectiveness. Presented at the Royal College of Physicians and Surgeons of Canada Annual Meeting, Vancouver, British Columbia, September, 1993. McEwan AJB, Porter A, McGowan D, Amyotte G, MacGillivray J, Berringer J, Member of the Trans Canada Collaborative Group.

The effect of circulating PSA on the localisation and diagnostic ability of ^{99m}Tc-labelled anti-PSA MAb B80.3. Presented at the International Research Group on Immunoscintigraphy and Therapy, Nijmegen, Netherlands, March, 1992. Boniface GR, McEwan AJB, Baum RP, MacLean GD, Golberg, LE, Noujaim AA.



SCIENTIFIC EXHIBITS - CONTINUED

An evaluation of MAb 170H.82 in breast cancer. Poster at The Fourth Conference on Radioimmuno-detection and Radioimmunotherapy of Cancer, Princeton, New Jersey, September, 1992.

Conference on Chemical Modifiers in Cancer Treatment, Clearwater, Florida, February, 1991. Moore RB, Chapman JD, McPhee MS, McEwan AJB.

Clinical Experience with 123I-Iodoazomycin arabinoside (123I-IAZA): A potential non-invasive marker for hypoxia. 7th International Conference on Chemical Modifiers in Cancer Treatment, Clearwater, Florida, February, 1991. Parliament MB, Chapman JD, Urtasun RC, McEwan AJB, Mercer JR, Mannan RH, Wiebe LI.

A pharmacokinetic analysis of two novel monoclonal antibodies: Preliminary results from Phase I clinical trials. Prairie Provinces Chapter, Society of Nuclear Medicine, Banff, Alberta, April, 1991. McQuarrie SA, McEwan AJB, Golberg L, MacLean GD, Sykes TR, Noujaim AA.

HMPAO distribution in obsessive-compulsive disorder: A potential diagnostic indicator. Prairie Provinces Chapter, Society of Nuclear Medicine, Banff, Alberta, April, 1991. McEwan AJB, Herman B, Hooper HR, Warneke L.

Thallium-201 imaging to follow-up of differentiated thyroid carcinoma. Prairie Provinces Chapter, Society of Nuclear Medicine, Banff, Alberta, April, 1991. McEwan AJB, Tracey KP, Catz Z, Glazebrooke GA, Morrish DW.

Non-invasive probes for tumour hypoxia. Presented at ARCON Workshop, Grey Laboratories, UK, June, 1991. Parliament MB, Urtasun RC, McEwan AJB, Golberg L, Mercer JR, Mannan RH, Wiebe LI.

Treatment of Patients with Metastatic Carcinoid Tumor with 131-I Meta Iodobenzylguanidine (mIBG). Annual Meeting of the Royal College of Physicians and Surgeons of Canada, Québec, P.Q., September, 1991. Fields ALA, McEwan AJB, Schmidt RP, Catz Z, Hooper HR, Sloboda RS, MacDonald RN.

Radiotherapy and HMPAO Distribution. Prairie Provinces Chapter, Society of Nuclear Medicine, Banff, Alberta, April, 1991. McEwan AJB, Hooper HR, Urtasun R, Huyser-Wierenger D, Catz Z.

Treatment of patients with malignant pheochromocytoma with 131-I meta iodobenzylguanidine (mIBG). Poster at Alberta Cancer Board Annual Scientific Meeting, Kananaskis, November, 1991.

Treatment of patients with metastatic carcinoid tumor with 131-I meta iodobenzylguanidine (mIBG). Poster at Alberta Cancer Board Annual Scientific Meeting, Kananaskis, November, 1991.

Preserved facial discrimination despite severe visual perceptual deficits: A single case report. Canadian Psychological Association, November, 1990. Kiss I, Rowe D, McEwan AJB.

Three-Dimensional Quantitative Analysis of Cerebral Perfusion from HMPAO SPECT Images: Normal and Pathophysiological Data. 5th Congress, Federation of Nuclear Medicine and Biology, Montreal, August, 1990. McEwan AJB, Hooper HR, Kotchon T, McTeer P, Hooper PM.

Initial Clinical Experience with Tc-99m 170H.82, a Novel Panadenocarcinoma Monoclonal Antibody. 5th Congress, Federation of Nuclear Medicine and Biology, Montreal, August, 1990. McEwan AJB, MacLean GD, Longenecker BM, Golberg L, Sykes TR, Noujaim AA.

Potentiation of Photodynamic Therapy by Bioreductive Chemotherapy. IPA 3rd Biennial Meeting, January, 1990. Moore RB, Chapman JD, Mokranowski AD, Meeker BE, Stobbe CC, McEwan AJB, McPhee MS.

**SCIENTIFIC EXHIBITS - CONTINUED**

Biological considerations in the evaluation of tumor-directed monoclonal antibodies for radioimmunoscintigraphy. International Symposium on Radiopharmacology, Sydney, Australia, August, 1989. Sykes TR, Noujaim AA, McEwan AJB, MacLean GD.

Radioimmunoscintigraphy with MAb-155 in patients with adenocarcinoma. International Symposium on Radiopharmacology, Sydney, Australia, August, 1989. Sykes TR, McEwan AJB, Woo TK, Borowski AL, MacLean GD, Sykes CJ, Noujaim AA.

Clinical use of Tc-99m granulocytes in the localization of inflammatory foci. Annual Meeting, Prairie Provinces Chapter, Society of Nuclear Medicine, Edmonton, Alberta, April 6-8, 1989. Schmidt RP, McEwan AJB, Catz Z.

Immunoscintigraphy of lung adenocarcinoma using a novel monoclonal antibody. American Thoracic Society Annual Meeting, Las Vegas, May 8-11, 1988. Marcushamer S, MacLean GD, McEwan AJB, Longenecker BM, Sykes TR, Lukka H, Noujaim AA.

Nuclear medicine investigations in the development of a rational radioiodine ablation therapy of thyroid tissue in a patient with renal failure. Annual Meeting, Prairie Provinces Chapter, Society of Nuclear Medicine, Saskatoon, Sask. April 8-9, 1988. Schmidt RP, Morrish D, Kotchon T, Filipow L, Murland K, McEwan AJB.

Kinetic analysis of radioimmunoscintigraphy using a uniquely derived monoclonal antibody as diagnostic and prognostic significance. Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, 1988. MacLean GD, McEwan AJB, Catz Z, Selvaraj S, Suresh MR, Sykes TR, Abdi E, Fields ALA, Noujaim AA, Longenecker BM.

Radioimmunoimaging with monoclonal antibodies against synthetic antigen: Correlation with tumor blood flow. Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, 1988. MacLean GD, McEwan AJB, Catz Z, Selvaraj S, Suresh MR, Sykes TR, Abdi E, Fields ALA, Noujaim AA, Longenecker BM.

Cancer imaging with a monoclonal antibody of predetermined specificity, derived using a synthetic carbohydrate. International Conference on MAbs Immunoconjugates for Cancer, March 1987. MacLean GD, McEwan AJB, Catz Z, Selvaraj S, Suresh MR, Sykes TR, Abdi E, Fields ALA, Noujaim AA, Longenecker BM.

Lymph node evaluation using computerized tomography and immunolymphoscintigraphy in prostate cancer. The Royal College of Radiologists, Oxford, September, 1987. Porter AT, Lukka HR, McEwan AJB, MacLean GD.

Localization of gynecologic cancers using a new monoclonal antibody derived against a synthetic carbohydrate--therapeutic implications. First meeting of the International Gynecologic Cancer Society, Amsterdam, 1987. MacLean GD, McEwan AJB, Sykes TR, Suresh MR, Henningson C, Noujaim AA, Longenecker BM.

Comparison of radiolabelled monoclonal antibody imaging with assessment of tumor blood flow. Alberta Heritage Foundation for Medical Research Days, November 1987. Seethram K, McEwan AJB, Hooper HR, MacLean GD, Catz Z.

Kinetic imaging with ¹²³I meta iodobenzylguanidine in diabetic autonomic neuropathy. Alberta Heritage Foundation for Medical Research Days. November, 1987. Muldowney SM, Ryan EA, Seethram K, Kappagoda CT, McEwan AJB.

Uptake of Tc-99m hexamethylpropylene amine oxime (HMPAO) by metastatic renal cell carcinoma. Canadian Nuclear Medicine Meeting, Quebec City, December, 1987. McEwan AJB, Catz Z, Schmidt RP, Porter AT, Venner PM, Seethram K, Hooper HR.



SCIENTIFIC EXHIBITS - CONTINUED

Tc-99m radioaerosol lung permeability as an early indicator of treatment induced pneumonitis in lung cancer. Canadian Nuclear Medicine Meeting, Quebec City, December 1987
McEwan AJB, Catz Z, Hooper HR

Monoclonal antibodies against synthetic antigens to detect cancer. Alberta Heritage Research Days, November 7, 1986.
McEwan AJB, MacLean GD, Suresh MR, Noujaim AA, Longenecker BM

Radiolabelled meta iodobenzylguanidine in the management of pheochromocytoma. 4th Annual Meeting, British Endocrine Societies, March 25-29, 1984.
McEwan AJB, Arkerv DM